

(in which pA is an integer having a value of from 0 to 1 and qA is an integer having a value of from 2 to 3 and wherein the double bond of such bicycloalkenyl is in the qA bridge);

R^{4A} is together with R^{3A} forms a cycloalkyl or bicycloalkenyl as defined above, or together with R^{3A} is a methylene chain of 3 carbon atoms such that a cycloalkyl of 4 carbon atoms inclusive is formed;


R^{5A} is hydrogen atom or together with R^{4A} forms a cycloalkyl as defined above; and

R^{6A} is hydrogen atom or straight-chain alkyl having from 1 to 8 carbon atoms; are disclosed as having an inhibitory activity on prostaglandin like.

Disclosure of the invention

The present invention accordingly provides

(1) an ω -cycloalkyl-prostaglandin E₂ derivative of formula (I)



wherein R is carboxy or hydroxymethyl;

R¹ is oxo, methylene or halogen atom;

R² is hydrogen atom, hydroxy or C1-4 alkoxyl;

R³ is hydrogen atom, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl or C2-8 alkynyl substituted by 1-3 substituents selected from (1)-(5);

(1) halogen atom,

(2) C1-4 alkoxyl,

(3) C3-7 cycloalkyl,

(4) phenyl, and

(5) phenyl substituted by 1-3 substituents selected from halogen atom, C1-4 alkyl, C1-4 alkoxyl, nitro and trifluoromethyl;

n is 0-4;



is single bond or double bond;



is double bond or triple bond; and



is a single bond, double bond or triple bond;


and wherein the double bond at the 13-14 position, when present, is in the E, Z or EZ mixture form; with the proviso that when the 5-6 position is a triple bond, the 13-14 position is not a triple bond; or a non-toxic salt thereof, prodrug thereof or cycloaddition adduct thereof;

(2) processes for the preparation thereof; and

(3) pharmaceutical agents containing such a derivative as an active ingredient.


In the present invention, prodrug means

1) for compounds of formula (I) of the present invention, those in which R represents COOR¹⁰ (in which R¹⁰ is C1-6 alkyl), i.e. the compounds of formula (IA)




wherein all symbols are as heretofore defined,

2) for compounds of formula (I) of the present invention, those in which R represents CONR¹²R¹³ (in which R¹² and R¹³ each, independently, is hydrogen atom or C1-6 alkyl), i.e. the compounds of formula (IB)



wherein all symbols are as hereinbefore defined, or
 3) for compounds of formula (I) of the present invention, those in which R represents COOR¹⁰ (in which R¹⁰ is as hereinbefore defined), R¹ represents R¹¹-COO (in which R¹¹ is C1-4 alkyl, C1-4 alkoxy, phenyl, phenyl-C1-4 alkyl, R¹⁴-COO-C1-4 alkyl or R¹⁴-COO-C2-4 alkenyl (in which R¹⁴ is hydrogen atom or C1-4 alkyl) and 8-9 position is double bond, i.e. the compounds of formula (IC)



wherein all symbols are as hereinbefore defined.

In formula (I) or (IC), C1-4 alkyl in the definitions of R², R¹¹ and R¹⁴ means methyl, ethyl, propyl, butyl and isomers thereof.

In formula (I), (IA) or (IB), C1-8 alkyl represented by R¹⁰, R¹² and R¹³ means methyl, ethyl, propyl, butyl, pentyl, hexyl and isomers thereof.

In formula (I), C1-8 alkyl represented by R² means methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl and isomers thereof.

In formula (I), C2-4 alkenyl in the definition of R¹¹ means vinyl, propenyl, butenyl and isomers thereof.

In formula (I), C2-8 alkenyl represented by R² means vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl and isomers thereof.

In formula (I), C2-8 alkenyl represented by R² means ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl and isomers thereof.

In formula (I), or (IC), C1-4 alkoxy in the definitions of R², R¹¹ and R¹⁴ means methoxy, ethoxy, propoxy, butoxy and isomers thereof.

In formula (I), C3-7 cycloalkyl in the definition of R² means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

In formula (I), a halogen atom in the definition of R¹ and R² means fluorine, chlorine, bromine and iodine.


In the present invention, it may be easily understood by those skilled in the art, unless otherwise specified, the symbol:



Indicates that the substituent attached thereto is in front of the sheet, unless otherwise specified, the symbol:



Indicates that the substituent attached thereto is behind the sheet, unless otherwise specified, the symbol:




Indicates that the substituent attached thereto is a mixture of in front of and behind the sheet or may be in front of or behind the sheet.

Unless otherwise specified, all isomers are included in the present invention. For example, the alkyl, alkenyl and alkenyl groups include straight-chain and also branched-chain ones. The double bond in alkenyl group includes E, Z and E,Z mixtures. Isomers generated by the existence of asymmetric carbon atom(s) e.g. in branched-chain alkyl are included in the present invention.


Preferred compounds of the present invention include compounds of the formula (I) listed in the examples or in Tables 1-14 or prodrugs thereof.

[Table 1]




No.	n	R ³	No.	n	R ³
1	0	CH ₃	11	1	CH ₃
2	0	CH ₃	12	1	CH ₃
3	0	CH ₃	13	1	CH ₃
4	0	CH ₃	14	1	CH ₃
5	0	CH ₃	15	1	CH ₃
6	0	CH ₃	16	1	CH ₃
7	0	CH ₃	17	1	CH ₃
8	0	CH ₃	18	1	CH ₃
9	0	CH ₃	19	1	CH ₃
10	0	CH ₃	20	1	CH ₃

[Table 2]




No.	n	R ³	No.	n	R ³
1	0	CH ₃	11	1	CH ₃
2	0	CH ₃	12	1	CH ₃
3	0	CH ₃	13	1	CH ₃
4	0	CH ₃	14	1	CH ₃
5	0	CH ₃	15	1	CH ₃
6	0	CH ₃	16	1	CH ₃
7	0	CH ₃	17	1	CH ₃
8	0	CH ₃	18	1	CH ₃
9	0	CH ₃	19	1	CH ₃
10	0	CH ₃	20	1	CH ₃

[Table 3]























No.	n	R ³	No.	n	R ³
1	0	CH ₃	11	1	CH ₃
2	0	CH ₃	12	1	CH ₃
3	0	CH ₃	13	1	CH ₃
4	0	CH ₃	14	1	CH ₃
5	0	CH ₃	15	1	CH ₃
6	0	CH ₃	16	1	CH ₃
7	0	CH ₃	17	1	CH ₃
8	0	CH ₃	18	1	CH ₃
9	0	CH ₃	19	1	CH ₃
10	0	CH ₃	20	1	CH ₃


[Table 4]























No.	n	R ³	No.	n	R ³
1	0	CH ₃	11	1	CH ₃
2	0	CH ₃	12	1	CH ₃
3	0	CH ₃	13	1	CH ₃
4	0	CH ₃	14	1	CH ₃
5	0	CH ₃	15	1	CH ₃
6	0	CH ₃	16	1	CH ₃
7	0	CH ₃	17	1	CH ₃
8	0	CH ₃	18	1	CH ₃
9	0	CH ₃	19	1	CH ₃
10	0	CH ₃	20	1	CH ₃


[Table 5]

No.	n	R ³	No.	n	R ³
1	0		11	1	
2	0		12	1	
3	0		13	1	
4	0		14	1	
5	0		15	1	
6	0		16	1	
7	0		17	1	
8	0		18	1	
9	0		19	1	
10	0		20	1	




[Table 6]

No.	n	R ³	No.	n	R ³
1	0		11	1	
2	0		12	1	
3	0		13	1	
4	0		14	1	
5	0		15	1	
6	0		16	1	
7	0		17	1	
8	0		18	1	
9	0		19	1	
10	0		20	1	




[Table 7]




No.	n	R ³	No.	n	R ³
1	0	CH ₃	11	1	CH ₃
2	0	CH ₃	12	1	CH ₃
3	0	CH ₃ CH ₃	13	1	CH ₃ CH ₃
4	0	CH ₃	14	1	CH ₃
5	0	CH ₃	15	1	CH ₃
6	0	CH ₃	16	1	CH ₃
7	0	CH ₃	17	1	CH ₃
8	0	CH ₃	18	1	CH ₃
9	0	CH ₃	19	1	CH ₃
10	0	CH ₃	20	1	CH ₃

[Table 8]




No.	n	R ³	No.	n	R ³
1	0	CH ₃	11	1	CH ₃
2	0	CH ₃	12	1	CH ₃
3	0	CH ₃ CH ₃	13	1	CH ₃ CH ₃
4	0	CH ₃	14	1	CH ₃
5	0	CH ₃	15	1	CH ₃
6	0	CH ₃	16	1	CH ₃
7	0	CH ₃	17	1	CH ₃
8	0	CH ₃	18	1	CH ₃
9	0	CH ₃	19	1	CH ₃
10	0	CH ₃	20	1	CH ₃

(Table 9)



No.	n	R ³	No.	n	R ³
1	0	CH ₃	11	1	CH ₃
2	0	CH ₃	12	1	CH ₃
3	0	CH ₃	13	1	CH ₃
4	0	CH ₃	14	1	CH ₃
5	0	CH ₃	15	1	CH ₃
6	0	CH ₃	16	1	CH ₃
7	0	CH ₃	17	1	CH ₃
8	0	CH ₃	18	1	CH ₃
9	0	CH ₃	19	1	CH ₃
10	0	CH ₃	20	1	CH ₃


(Table 10)



No.	n	R ³	No.	n	R ³
1	0	CH ₃	11	1	CH ₃
2	0	CH ₃	12	1	CH ₃
3	0	CH ₃	13	1	CH ₃
4	0	CH ₃	14	1	CH ₃
5	0	CH ₃	15	1	CH ₃
6	0	CH ₃	16	1	CH ₃
7	0	CH ₃	17	1	CH ₃
8	0	CH ₃	18	1	CH ₃
9	0	CH ₃	19	1	CH ₃
10	0	CH ₃	20	1	CH ₃


[Table 11]

No.	n	R ³	No.	n	R ³
1	0	CH ₃	11	1	CH ₃
2	0	CH ₂	12	1	CH ₃
3	0	CH(CH ₃) ₂	13	1	CH(CH ₃) ₂
4	0	CH=CH ₂	14	1	CH=CH ₂
5	0	CH=CH ₂	15	1	CH=CH ₂
6	0	CH=CH ₂	16	1	CH=CH ₂
7	0	CH=CH ₂	17	1	CH=CH ₂
8	0	CH=CH ₂	18	1	CH=CH ₂
9	0	CH=CH ₂	19	1	CH=CH ₂
10	0	CH=CH ₂	20	1	CH=CH ₂




[Table 12]

No.	n	R ³	No.	n	R ³
1	0	CH ₃	11	1	CH ₃
2	0	CH ₂	12	1	CH ₃
3	0	CH(CH ₃) ₂	13	1	CH(CH ₃) ₂
4	0	CH=CH ₂	14	1	CH=CH ₂
5	0	CH=CH ₂	15	1	CH=CH ₂
6	0	CH=CH ₂	16	1	CH=CH ₂
7	0	CH=CH ₂	17	1	CH=CH ₂
8	0	CH=CH ₂	18	1	CH=CH ₂
9	0	CH=CH ₂	19	1	CH=CH ₂
10	0	CH=CH ₂	20	1	CH=CH ₂




[Table 13]



No.	n	R ³	No.	n	R ³
1	0	CH ₃	11	1	CH ₃
2	0	CH ₃	12	1	CH ₃
3	0	CH ₃	13	1	CH ₃
4	0	CH ₃	14	1	CH ₃
5	0	CH ₃	15	1	CH ₃
6	0	CH ₃	16	1	CH ₃
7	0	CH ₃	17	1	CH ₃
8	0	CH ₃	18	1	CH ₃
9	0	CH ₃	19	1	CH ₃
10	0	CH ₃	20	1	CH ₃

[Table 14]



No.	n	R ³	No.	n	R ³
1	0	CH ₃	11	1	CH ₃
2	0	CH ₃	12	1	CH ₃
3	0	CH ₃	13	1	CH ₃
4	0	CH ₃	14	1	CH ₃
5	0	CH ₃	15	1	CH ₃
6	0	CH ₃	16	1	CH ₃
7	0	CH ₃	17	1	CH ₃
8	0	CH ₃	18	1	CH ₃
9	0	CH ₃	19	1	CH ₃
10	0	CH ₃	20	1	CH ₃

Salts


The compounds of formula (I) of the present invention may be converted into a corresponding non-toxic salt by methods known per se. Non toxic and water-soluble salts are preferable. Suitable salts, for example, are salts of an alkali metal (potassium, sodium etc.), salts of an alkaline earth metal (calcium, magnesium etc.), ammonium salts and salts of pharmaceutically-acceptable organic amines (tetramethylammonium, triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, trihydroxymethylmethylamine, lysine, arginine, N-methyl-D-glucamine etc.).

Cyclo-oxygen synthetases


Cyclo-oxygen synthetases of α -cycloalkyl-prostaglandin E_2 derivatives of the formula (I) may be prepared by the method described in the specification of GB 1351233, which is herein incorporated by reference, using α -, β - or γ -cyclo-oxygen synthetase or a mixture thereof. Converting into their cyclo-oxygen synthetases serves to increase the stability and solubility in water of the compounds, and is therefore useful in the use for pharmaceuticals.

Processes for the Preparation

1) For compounds of formula (I) of the present invention, those in which R is carboxy, i.e., the compounds of formula (I-1)



wherein all the symbols are as heretofore defined may be prepared by hydrolysis using an enzyme or hydrolysis under alkaline conditions of a compound of formula (IA)




wherein all the symbols are as heretofore defined.


The hydrolysis using an enzyme is known. For example, hydrolysis may be carried out in a mixture of a water-miscible organic solvent (ethanol, dimethylsulfoxide etc.) and water, in the presence or absence of buffer, using an ester cleaving enzyme (esterase, lipase etc.), at a temperature of from 0 °C to 50 °C.

The hydrolysis under alkaline conditions is known. For example, hydrolysis may be carried out in a water-miscible organic solvent (ethanol, tetrahydrofuran, dioxan etc.), using aqueous solution of an alkali (sodium hydroxide, potassium hydroxide, potassium carbonates etc.), at a temperature of from -10 to 90 °C.


2) For compounds of formula (I) of the present invention, those in which R is hydroxymethyl and R1 is oxo, i.e. in the compounds of formula (I-2).



wherein all the symbols are as heretofore defined those in which R1 is oxo, i.e., the compounds of formula (I-2A)



wherein all the symbols are as heretofore defined may be prepared by elimination under acidic conditions of the protecting group(s) of a compound of formula (IIA)




wherein R10 is hydrogen atom, hydroxy protecting group which may be eliminated under acidic conditions or C1-4 alkoxy, R10 is hydroxy protecting group which may be eliminated under acidic conditions, and the other symbols are as heretofore defined.

The hydroxy protecting group which may be eliminated under acidic conditions includes, for example, t-butyldimethylsilyl, triphenylmethyl, tetrahydropyran-2-yl etc.


The hydrolysis under acidic conditions is known. For example, hydrolysis may be carried out in a water-miscible organic solvent (tetrahydrofuran, methanol, ethanol, dimethoxyethane, acetonitrile or mixture thereof etc.), using an inorganic acid (hydrochloric acid, phosphoric acid, hydrofluoric acid or hydrogen fluoride-pyridine etc.), or organic acid (acetic acid, p-toluenesulfonic acid, picric acid, etc.) at a temperature of from 0 to 50 °C.

3) For compounds of formula (I) of the present invention, those in which R is hydroxymethyl and R1 is methylene,


i.e., in the compounds of formula (I-2)



wherein all the symbols are as hereinbefore defined
those in which R¹ is methylene, i.e., the compounds of formula (I-2B)




wherein all the symbols are as hereinbefore defined may be prepared by reduction of a compound of formula (IA-4)




wherein all the symbols are as hereinbefore defined.

The reduction is known. For example, reduction may be carried out in an inert organic solvent (tetrahydrofuran (THF), hexane, toluene, etc.), using diisobutylaluminum hydride at a temperature of from -80 to 0 °C.


4) For compounds of formula (I) of the present invention, those in which R is hydroxymethyl and R¹ is halogen atom, i.e., in the compounds of formula (I-2)



wherein all the symbols are as hereinbefore defined
those in which R¹ is halogen atom, i.e., the compounds of formula (I-2C)




wherein R¹⁵ is halogen atom and the other symbols are as hereinbefore defined
may be prepared by reduction of a compound of formula (IA-5)




wherein all the symbols are as hereinbefore defined.

The reduction may be carried out by the same method as hereinbefore described.

5) For product compounds of formula (IA) of the present invention, those in which R² is hydrogen atom or hydroxy, i.e., the compounds of formula (IA-1)




wherein R^{22} is hydrogen atom or hydroxy and the other symbols are as hereinbefore defined
may be prepared by hydrolysis under acidic conditions of a compound of formula (III)




wherein R^{21} is hydrogen atom or hydroxy protecting group which may be eliminated under acidic conditions, and the other symbols are as hereinbefore defined.
The hydrolysis under acidic conditions may be carried out by the same method as hereinbefore described.

6) For producing compounds of formula (IA) of the present invention, those in which R^2 is C1-4 alkoxy, i.e., the compounds of formula (IA-2)




wherein R^{23} is C1-4 alkoxy and the other symbols are as hereinbefore defined may be prepared by O-alkylation of a compound of formula (IA-1) in which R^{22} is hydroxy, i.e., a compound of formula (IA-3)



wherein all the symbols are as hereinbefore defined.

O-alkylation is known. For example, O-alkylation may be carried out in an inert organic solvent (THF, diethyl ether, etc.), using diazoalkane at a temperature of from -30 to 40 °C or in an inert organic solvent (acetonitrile, etc.), in the presence of silver oxide, using alkyl iodide at a temperature of from 0 to 40 °C.

7) The producing compounds of formula (IB) of the present invention may be prepared by amidation of a compound of formula (I-1)




wherein all the symbols are as hereinbefore defined with a compound of formula (IV)



wherein all the symbols are as hereinbefore defined.

Amidation is known. For example, amidation may be carried out in an inert organic solvent (THF, dichloromethane, benzene, acetone, acetonitrile or mixture thereof, etc.), in the presence or absence of tertiary amine (dimethylaminopiperidine, pyridine, triethylamine, etc.), using condensing agent (1,3-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylamino) propylcarbodiimide (EDC), etc.) at a temperature of from 0 to 50 °C.


8) The producing compounds of formula (IC) of the present invention may be prepared by hydrolysis under acidic conditions of a compound of formula (V)



wherein all the symbols are as hereinbefore defined.


The hydrolysis under acidic conditions may be carried out by the same method as hereinbefore described. The compound of the formula (IIA) may be prepared according to the reaction of the following Scheme (V). The compound of the formula (V) may be prepared according to the reaction of the following Scheme (V). The compounds of formula (III) may be separated according to the values of R¹ and R²¹ into the following six classes of compounds. That is,

1) R¹ is oxo, R²¹ is hydroxy protecting group which may be eliminated under acidic conditions, i.e., the compound of formula (IIIA)




wherein R²⁴ is hydroxy protecting group which may be eliminated under acidic conditions, and the other symbols are as hereinbefore defined.

2) R¹ is methylene, R²¹ is hydroxy protecting group which may be eliminated under acidic conditions, i.e., the compound of formula (IIIB)




wherein all the symbols are as hereinbefore defined.

3) R¹ is halogen atom, R²⁴ is hydroxy protecting group which may be eliminated under acidic conditions, i.e., the compound of formula (IIIC)




wherein R¹⁵ is halogen atom and the other symbols are as hereinbefore defined.

4) R¹ is oxo, R²¹ is hydrogen atom, i.e., the compound of formula (IIID)




wherein all symbols are as hereinbefore defined.

5) R¹ is methylene, R²¹ is hydrogen atom, i.e., the compound of formula (IIIE)



wherein all symbols are as hereinbefore defined.

6) R¹ is halogen atom, R²¹ is hydrogen atom, i.e., the compound of formula (IIIF)



wherein all symbols are as heretofore defined.

The compound of the formula (IIIB) may be prepared from the compound of the formula (IIA) according to the reaction of the following Scheme (A).

The compound of the formula (IIIC) may be prepared from the compound of the formula (IIIA) according to the reaction of the following Scheme (B), (C) or (D).

The compound of the formula (IIID) may be prepared from the compound of the formula (IIIA) according to the reaction of the following Scheme (E).

The compound of the formula (IIIE) may be prepared from the compound of the formula (IIID) according to the same reaction of the following Scheme (A).

The compound of the formula (IIIF) may be prepared from the compound of the formula (IIID) according to the same reaction of the following Scheme (B), (C) or (D).

The compound of the formula (IIIA) may be prepared according to the reaction of the following Scheme (F), (G) or (H).

In the Scheme, the symbols represent the following meanings or are as heretofore defined.

Ts is p-toluenesulfonyl;

Ac is acetyl;

Ph is phenyl;

AIBN is 2,2'-azobisisobutyronitrile;

DIBAL is diisobutylaluminum hydride;

t-Bu is t-butyl;

n-Bu is normal butyl;

c-Hex is cyclohexyl;

Et is ethyl;

EE is ethoxyethyl;

D-(-)-DIPPT is D-(-)-diisopropyl tartrate;


L-(+)-DIPPT is L-(+)-diisopropyl tartrate;

Ti(OiPr)₄ is titanium (IV) isopropoxide;


TBHP is t-butylhydroperoxide;

Cp₂ZrCl₂ is bis(cyclopentadienyl)zirconium chloride hydride.


Scheme (A)




Scheme (B)




Scheme (C)




Scheme (D)




Scheme (E)




Scheme (F)




Scheme (G)




Scheme (H)




Scheme (J)




Scheme (K)




Scheme (L)



Schema (M)



Scheme (N)



Each reaction of hereinafter described reaction Schemes may be carried out by known methods. In the reaction Schemes, the compounds of formula (VI), (VIII), (X), (XII), (XIII), (X) and (XV) as starting materials are known per se.

or may be prepared by known methods.

For example, in the compound of formula (VI), (4RS)-5,6-propanodiol-1-yn-4-ol is known compound described in the specification of United States Patent No. 4,132,733.

In the compound of formula (VIII), (6Z)-7-(3R)-3-4-butyldimethylsilyloxy-5-oxocyclopent-1-enylhept-5-enoic acid methyl ester and in the compound of formula (X), (4R)-2-(diethylaminoethyl)-4-butyldimethylsilyloxy-2-cyclopent-1-one is known compound described in the literature of J. Org. Chem., 53, 5590-5592 (1988).

In the compound of formula (XII), (4R)-4-butyldimethylsilyloxy-2-cyclopent-1-one and in the compound of formula (XIII), 7-iodohex-5-enoic acid methyl ester is known compound described in the literature of J. Am. Chem. Soc., 110, No. 14, 4719-4725 (1988).

The compound of formula (XII) is known compound described in the literature of J. Am. Chem. Soc., 92, 4745-4746 (1975).

The starting materials and reagents in the present invention are known per se or may be prepared by known methods.

In each reaction in the present specification, obtained products may be purified by conventional techniques. For example, purification may be carried out by distillation at atmospheric or reduced pressure, by high performance liquid chromatography, by thin layer chromatography or by column chromatography using silica gel or magnesium silicate, by washing or by recrystallization. Purification may be carried out after each reaction, or after a series of reactions.

Pharmacological Activities

The compounds of the present invention of the formula (I) bind and act on EP₂ receptor which is a subtype of of PGE₂ receptor.

For example, in standard laboratory test, the effects of the compounds of the present invention were confirmed by binding assay using expression cell of prostaglandin receptor subtype.

Binding assay using expression cell of prostaglandin receptor subtype

The preparation of membrane fraction was carried out according to the method of Sugimoto et al., J. Biol. Chem., 267, 6463-6466 (1992), using expression CHO cell of the prostaglandin receptor subtype (mouse EP₁, EP₂, EP_{3a}, EP₄). The standard assay mixture containing membrane fraction (0.5 mg/ml), and [³H]-PGE₂ in a final volume of 200 μ l was incubated for 1 hour at room temperature. The reaction was terminated by the addition of 3 ml of ice-cold buffer. The mixture was rapidly filtered through a GF/B glass filter. The radioactivity associated with the filter was measured by liquid scintillation counting.

Kd and Bmax values were determined from Scatchard plots [Ann. N.Y. Acad. Sci., 51, 660 (1949)]. Non-specific binding was calculated as the binding in the presence of an excess (2.5 μ M) of unlabeled PGE₂. In the experiment for competition of specific [³H]-PGE₂ binding by the compounds of the present invention, 2.5 nM of [³H]-PGE₂ and various concentrations of compounds of the present invention were added. The following buffer was used in all reactions.

Buffer: 10 mM potassium phosphate (pH 6.0), 1 mM EDTA, 10 mM MgCl₂, 0.1M NaCl

All of the values shown are those obtained using the more polar stereoisomer of the exemplified compounds.

The dissociation constant (Ki) of each compound was calculated by the following equation.

$$Ki = IC_{50} / (1 + ([C]/Kd))$$

The results are shown in Table 15.

Table 15

Example No.	Ki (μ M)			
	EP ₁	EP ₂	EP _{3a}	EP ₄
4	>10	0.092	>10	>10
4(5)	>10	0.032	>10	>10
4(10)	>10	0.030	>10	>10
6(1)	>10	0.038	>10	>10

Table 15 (continued)

Example No.	Ki (μ M)			
	EP ₁	EP ₂	EP _{3a}	EP ₄
6(5)	>10	0.076	>10	>10
10	>10	0.034	>10	>10
12	>10	0.37	>10	>10
16(1)	>10	0.096	>10	>10
17(2)	1.10	0.009	2.70	0.40

Toxicity

The toxicity of the compounds of the present invention is very low and therefore, it is confirmed that these compounds are safe for pharmaceutical use.

Application for Pharmaceuticals

The compounds of the present invention of the formula (I) bind strongly and act on PGE₂ receptor, especially on EP₂ subtype receptor and therefore are useful for prevention and/or treatment of immunological diseases (autoimmune diseases, organ transplantation, etc.), asthma, abnormal bone formation, neuronal cell death, liver damage, abortion, premature birth or retina neuropathy of glaucoma etc.

Among the compounds of the present invention of the formula (I), compounds which bind weakly on to receptor subtypes except for EP₂ receptors and other arachidonic acid metabolism receptors (thromboxane receptor, PGE₂ receptor, etc.) do not express other effects and therefore it is thought that such compounds will be a medical agent which have less side-effects.

For the purpose above described, the compounds of the formula (I), (IA), (IB) and (IC), produce thereof, non-toxic salts thereof and cyclooctatin diastere thereof may be normally administered systemically or partially, usually by oral or parenteral administration. To convert prodrug, they have merit of non-stimulant, good-absorbability, good-solubility, etc. The doses to be administered are determined depending upon age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment etc. In the human adult, the doses per person per dose are generally from 1 μ g to 100 mg, by oral administration, up to several times per day, and from 0.1 μ g to 10 mg, by parenteral administration (preferred into vein) up to several times per day, or continuous administration for from 1 to 24 hrs. per day into vein.

As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.

The compounds of the present invention may be administered in the form of, for example, solid compositions, liquid compositions or other compositions for oral administration, or injections, liniments or suppositories etc. for parenteral administration.

Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules.

Capsules include hard capsules and soft capsules.

In such compositions, one or more of the active compound(s) is or are, admixed with at least one inert diluent such as lactose, mannitol, maltitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, magnesium metasilicate aluminates. The compositions may also comprise, as is normal practice, additional substances other than inert diluents: e.g. lubricating agents such as magnesium stearate, disintegrating agents such as cellulose calcium glycolate, and assisting agents for dissolving such as glutamic acid, aspartic acid. The tablets or pills may, if desired, be coated with film of gastric or enteric material such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropyl cellulose phthalate etc., or be coated with two or more films. And further, coating may include containment within capsules of absorbable materials such as gelatin.

Liquid compositions for oral administration include pharmaceutically-acceptable emulsions, solutions, syrups and elixirs etc. In such liquid compositions, one or more of the active compound(s) is or are comprised in inert diluent(s) commonly used in the art (for example, purified water, ethanol etc.). Besides inert diluents, such compositions may also comprise adjuvants such as wetting agents, suspending agents, sweetening agents, flavouring agents, perfuming agents and preserving agents.

Other compositions for oral administration include spray compositions which may be prepared by known methods

and which comprise one or more of the active compound(s). Spray compositions may comprise additional substances other than inert diluents: e.g. stabilizing agents such as sodium hydrogen sulfate, stabilizing agents to give isotonicity, isotonic buffer such as sodium chloride, sodium citrate, citric acid. For preparation of such spray compositions, for example, the method described in the United States Patent No. 2868691 or 3095353 may be used.

Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Aqueous solutions or suspensions include distilled water for injection and physiological salt solution. Non-aqueous solutions or suspensions include propylene glycol, polyethylene glycol, plant oil such as olive oil, alcohol such as ethanol, POLYSORBATE® (registered trade mark) etc. Such compositions may comprise additional diluents: e.g. preservative agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agent, assisting agents such as assisting agents for dissolving (for example, glutamic acid, aspartic acid). They may be sterilized for example, by filtration through a bacteria-retaining filter, by incorporation of sterilizing agents in the compositions or by irradiation. They also be manufactured in the form of sterile solid compositions and which can be dissolved in sterile water or some other sterile diluents for injection immediately before used.


Other compositions for parenteral administration include liquids for external use, and endermic liniments, ointment, suppositories and pessaries which comprise one or more of the active compound(s) and may be prepared by known methods.

Reference examples and Examples

The following reference examples and examples are intended to illustrate, but not limit, the present invention. The solvents in parentheses show the developing or eluting solvents and the ratios of the solvents used are by volume in chromatographic separations. NMR in the parentheses show measured solvents. In the example, TBS is *t*-butyldimethylsilyl, THP is tetrahydropyran, Ac is acetyl, EE is ethoxyethyl.

Reference example 1

(4R)-4-*t*-butyldimethylsilyloxy-5,5-propanocta-1-yne




To the mixture solution of (4R)-5,5-propanocta-1-yne-4-ol (4.0 g) and imidazole (4.9 g) in dimethylformamide (50 ml) was added *t*-butyldimethylsilylchloride (5.4 g) under cooling with ice. The reaction mixture was stirred at 50 °C for 7 hours. The reaction mixture was quenched by addition of water, extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane → ethyl acetate = 10:1) to give the title compound (6.8 g) having the following physical data.

TLC: Rf 0.64 (hexane);

NMR (CDCl₃): δ 3.75 (1H, t, J=5.8 Hz), 2.28 (1H, ddd, J=17, 5.0, 2.5 Hz), 2.16 (1H, ddd, J=17, 6.0, 2.5 Hz), 2.10-1.94 (1H, m), 1.92 (1H, t, J=2.5 Hz), 1.90-1.20 (9H, m), 0.90 (3H, t, J=6.0 Hz), 0.89 (9H, s), 0.12 (3H, s), 0.07 (3H, s).

Reference example 2

(1E,4R)-1-iodo-4-*t*-butyldimethylsilyloxy-5,5-propanocta-1-ene




To the mixture of the compound prepared in reference example 1 (3.0 g) and *t*-butyldimethylsilylchloride (3.7 ml) was added azobisisobutyronitrile (35 mg). The mixture was stirred at 80 °C for 1.5 hours. After the mixture was cooled to room temperature, to the mixture was added dropwise iodine (4.1 g) in dichloromethane (70 ml). The reaction mixture was stirred for 10 min. To the reaction mixture was added a saturated aqueous solution of sodium bisulfite, ethyl acetate and a saturated aqueous solution of sodium chloride, stirred, filtered, and extracted. The water layer was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane) to give the title compound (3.9 g) having the following physical data.

TLC: Rf 0.77 (hexane);

NMR (CDCl₃): δ 6.49 (1H, dt, J=14.5, 7.5 Hz), 5.97 (1H, d, J=14.5 Hz), 3.58 (1H, t, J=6.0 Hz), 2.20-1.20 (12H, m), 0.91 (3H, t, J=6.0 Hz), 0.91 (9H, s), 0.06 (3H, s), 0.05 (3H, s).

Reference example 3

(5Z,11a,13E,16R)-11,16-bis(*t*-butyldimethylsilyloxy)-9-oxo-17,17-propanoocta-5,13-diene acid · methyl ester




To a solution of (1E,4R)-1-iodo-4-*t*-butyldimethylsilyloxy-5,5-propanocta-1-ene (368 mg) in ether (8 ml) was added dropwise 1.7 M *t*-butyllithium in pentane solution (1.06 ml) at -78 °C. After the mixture was stirred for 45 min, to the mixture was added 0.25 M lithium 2-phenylpropanoate in tetrahydrofuran (4.33 ml). After the mixture was stirred for 20 min at same temperature, to the mixture was added dropwise a solution of (5Z)-7-(3R)-3-*t*-butyldimethylsilyloxy-5-oxocyclopenta-1-ene)hepta-5-enoic acid · methyl ester (280 mg) in ether (4 ml). The reaction mixture was warmed up to 0 °C for 1 hour. The reaction mixture was quenched by addition of a saturated aqueous solution of ammonium chloride, extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of ammonium chloride and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 25 : 1) to give the title compound (332 mg) having the following physical data.

TLC: Rf 0.37 (hexane : ethyl acetate = 10 : 1);

NMR (CDCl₃) : δ 6.75-5.45 (1H, m), 5.45-5.20 (3H, m), 4.01 (1H, q, J=7.0 Hz), 3.66 (3H, s), 3.57 (1H, t, J=4.5 Hz), 2.60 (1H, dd, J=17.5, 6.5 Hz), 2.54-2.24 (3H, m), 2.30 (2H, t, J=7.0 Hz), 2.24-1.96 (6H, m), 1.96-1.20 (12H, m), 0.95 (3H, m), 0.91 (9H, s), 0.88 (9H, s), 0.06 (3H, s), 0.04 (3H, s), 0.03 (3H, s), 0.03 (3H, s).

Reference example 4

(4R)-4-*t*-butyldimethylsilyloxy-5,5-propanoocta-1-ene




To a solution of the compound prepared in reference example 2 (629 mg) in anhydrous ether (10 ml) was added dropwise 1.57 M *t*-butyllithium in pentane solution (1.96 ml) at -78 °C. The reaction mixture was stirred for 1 hour. The reaction mixture was quenched by addition of a saturated aqueous solution of ammonium chloride (20 ml), extracted with hexane (x2). The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane) to give the title compound (484 mg) having the following physical data.

TLC: Rf 0.75 (hexane);

NMR (CDCl₃) : δ 5.83 (1H, dd, J=17, 9.8, 7.4 Hz), 5.09-4.92 (2H, m), 3.59 (1H, dd, J=6.0, 4.8 Hz), 2.20-2.00 (2H, m), 2.00-1.20 (10H, m), 0.90 (3H, t, J=5.0 Hz), 0.63 (9H, s), 0.03 (6H, s).

Reference example 5

(4R)-4-*t*-butyldimethylsilyloxy-5,5-propanoocta-1-ol




To a borane-tetrahydrofuran complex (2.3 ml, 1.0 M tetrahydrofuran solution) was added dropwise cyclohexane (468 μl) at 0 °C under an atmosphere of argon. The mixture was stirred for 1.5 hours. To the mixture was added dropwise a solution of the compound prepared in reference example 4 (434 mg) in tetrahydrofuran (10 ml) at 0 °C. The reaction mixture was stirred for 30 min at same temperature, and stirred for 80 min at room temperature. To the reaction was added 1N aqueous solution of sodium hydroxide and 31% aqueous solution of hydrogen peroxide (3 ml). The mixture was stirred at room temperature for 30 min. The reaction mixture was quenched by addition of a saturated aqueous solution of sodium thiosulfate (5 ml), extracted with ether. The extract was washed with a saturated aqueous solution of sodium thiosulfate and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane → ethyl acetate) to give the title compound (439 mg) having the following physical data.

TLC: Rf 0.52 (hexane : ethyl acetate = 4 : 1);

NMR (CDCl₃) : δ 3.67 (2H, t, J=6.2 Hz), 3.55 (1H, t, J=4.6 Hz), 2.18-1.20 (14H, m), 0.95-0.85 (12H, m), 0.05 (6H, s).

Reference example 6

(4R)-4-*t*-butyldimethylsilyloxy-1-oxo-5,5-propanooctane




To a solution of the compound prepared in reference example 5 (430 mg) in anhydrous benzene (10 ml) was successively added imidazole (243 mg), triphenylphosphine (936 mg) and iodine (726 mg). The reaction mixture was stirred for 15 min. The reaction mixture was quenched by addition of a saturated aqueous solution of sodium thiosulfate, extracted with benzene (x2). The extract was washed with a saturated aqueous solution of sodium chloride (x2), dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane) to give the title compound (553 mg) having the following physical data.

TLC: Rf 0.63 (hexane);

NMR (CDCl₃) : δ 3.94 (1H, t, J=5.0 Hz), 3.16 (2H, t, J=6.8 Hz), 2.17-1.22 (14H, m), 0.95-0.85 (12H, m), 0.09 (3H, s).

Reference example 7

(3R,4R)-4-*t*-butyldimethylsilyloxy-2-methyliden-3-((4R)-4-*t*-butyldimethylsilyloxy-5,5-propanoocta-1-yn-1-yl)cyclopentanone



To a solution of (4R)-4-*t*-butyldimethylsilyloxy-5,5-propanoocta-1-yn-1-ol (730 mg) in toluene (5 ml) was added dropwise 1.6 M *n*-butyllithium in hexane solution (1.6 ml). After the mixture was stirred for 30 min, to the mixture was added dropwise 0.95 M triethylaluminum chloride in hexane solution (2.95 ml). After the mixture was stirred for 30 min, to the mixture was added dropwise a solution of (4R)-2-(diethylaminomethyl)-4-*t*-butyldimethylsilyloxy-2-cyclopenten-1-one (595 mg) in toluene (8 ml). The reaction mixture was stirred at room temperature for 15 min. The reaction mixture was quenched by addition of a saturated aqueous solution of ammonium chloride and 2N aqueous solution of hydrochloric acid, extracted with hexane. The extract was washed with a saturated aqueous solution of sodium hydrogencarbonate,


dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 100 : 1) to give the title compound (364 mg) having the following physical data.

TLC: Rf 0.77 (hexane : ethyl acetate = 10 : 1);

NMR (CDCl₃) : δ 6.12 (1H, d, J=3.0 Hz), 5.33 (1H, d, J=3.0 Hz), 4.25 (1H, m), 3.71 (1H, t, J=5.3 Hz), 3.50-3.40 (1H, m), 2.70 (1H, dd, J=18.0, 6.4 Hz), 2.40-1.20 (13H, m), 0.95-0.82 (21H, m), 0.18-0.02 (12H, m).

Reference example 8

(2R,3R,4R)-4-(4-butyldimethylsilyloxy)-2-(2Z-7-(1-ethoxyethoxy)-hepta-2-en-1-yl)-3-((4R)-4-(4-butyldimethylsilyloxy)-5,5-propanodioxo-1-yne-1-yl) cyclopentanone




To a solution of (1Z)-1-hodo-6-(1-ethoxyethoxy)hexa-1-ene (537 mg) in ether (5 ml) was added dropwise 1.57 M t-butyldimethylsilylating reagent in pentane solution (2.30 ml) at -78 °C. After the mixture was stirred for 1.5 hours, the mixture was added to 0.25 M lithium 2-dimethylacrylate in tetrahydrofuran (8.00 ml). After the mixture was stirred for 30 min at same temperature, to the mixture was added dropwise a solution of the compound prepared in reference example 7 (606 mg) in ether (10 ml). The reaction mixture was warmed up to 0 °C for 1 hour. The reaction mixture was extracted with a saturated aqueous solution of ammonium chloride, extracted with hexane. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 60 : 1 → 30 : 1) to give the title compound (585 mg) having the following physical data.

TLC: Rf 0.57 (hexane : ethyl acetate = 8 : 1);

NMR (CDCl₃) : δ 5.57-5.28 (2H, m), 4.65 (1H, q, J=5.0 Hz), 4.32-4.03 (1H, m), 3.73-3.35 (5H, m), 2.74-2.50 (2H, m), 2.47-1.18 (29H, m), 0.96-0.80 (21H, m), 0.13-0.05 (12H, m).

Reference example 9

(5Z,11α,16RS)-11,16-bis(4-butyldimethylsilyloxy)-9-oxo-17,17-propanoproposta-6-ene-13-yne-1-ol




To a solution of the compound prepared in reference example 8 (643 mg) in methanol (14 ml) was added pyridinium p-toluenesulfonate (24 mg) at 0 °C. The reaction mixture was stirred at room temperature for 5 hours. The reaction mixture was quenched by addition of a saturated aqueous solution of sodium hydrogencarbonate, extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 10 : 1) to give the title compound (359 mg) having the following physical data.

TLC: Rf 0.37 (hexane : ethyl acetate = 4 : 1);

NMR (CDCl₃) : δ 5.60-5.30 (2H, m), 4.32-4.22 (1H, m), 3.70 (1H, t, J=6.0 Hz), 3.64 (2H, t, J=7.0 Hz), 2.72-2.50 (1H, m), 2.66 (1H, dd, J=17.5, 6.6 Hz), 2.47-1.32 (23H, m), 0.95-0.83 (21H, m), 0.18-0.03 (12H, m).

Reference example 10

(5Z,11α,16RS)-11,16-bis(4-butyldimethylsilyloxy)-9-oxo-17,17-propanoproposta-6-ene-13-yndic acid - methyl ester




To a solution of the compound prepared in reference example 9 (369 mg) in acetone (10 ml) was added dropwise Jones reagent (aqueous solution of chromium (VI) oxide and sulfuric acid, 2.0 M containing chromic acid, 1.0 ml) at 30 °C. The reaction mixture was stirred for 1 hour. To the reaction mixture added isopropyl alcohol (3 ml), diluted with water, extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride, dried

over anhydrous magnesium sulfate and concentrated until the volume of 50 ml. To the residue solution was added a solution of diazomethane in ether until the reaction solution changed yellow color. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 100 : 1) to give the title compound (257 mg) having the following physical data.

TLC: Rf 0.76 (hexane : ethyl acetate = 4 : 1);
NMR (CDCl₃): δ 5.49-5.35 (2H, m), 4.32-4.22 (1H, m), 3.69 (1H, t, J=4.8 Hz), 3.66 (3H, s), 2.73-2.61 (12H, m), 2.44-1.32 (20H, m), 2.31 (2H, t, J=7.6 Hz), 0.95-0.82 (21H, m), 0.13-0.06 (12H, m).

Reference example 11

(11a, 13E, 16RS)-11,16-bis(4-tert-butylphenylsilyl)oxy-9-oxo-17,17-propandiprost-13-ene-5-ynoic and : methyl ester




To a solution of (1E,4RS)-1-iodo-4-tert-butylphenylsilyl oxy-5,5-propandiprost-1-ene (265 mg) in ether (2 ml) was added dropwise 1.7 M n-butyllithium in pentane solution (0.63 ml) at -78 °C. After the mixture was stirred for 1 hour, to the mixture was added 0.25 M lithium 2-thienylcyclopropane in tetrahydrofuran (3.12 ml). After the mixture was stirred for 20 min at same temperature, to the mixture was added dropwise a solution of (4R)-4-tert-butylphenylsilyl oxy-2-cyclopenten-1-one (106 mg) in tetrahydrofuran (4 ml). The reaction mixture was warmed up to 20 °C for 30 min. To the reaction mixture was added dropwise a solution of 7-iodohepta-5-ynoic acid : methyl ester (665 mg) in tetrahydrofuran (5 ml). The reaction mixture was stirred for 3 hours. The reaction mixture was quenched by addition of a saturated aqueous solution of ammonium chloride, extracted with hexane. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 50 : 1 → 20 : 1) to give the title compound (44 mg) having the following physical data.

TLC: Rf 0.36 (hexane : ethyl acetate = 8 : 1);
NMR (CDCl₃): δ 5.78-5.55 (1H, m), 5.40-5.23 (1H, m), 4.10-3.95 (1H, m), 3.68 (3H, s), 3.65-3.53 (1H, m), 2.80-2.50 (2H, m), 2.50-1.20 (22H, m), 1.00-0.80 (3H, m), 0.91, 0.90 and 0.88 (18H, 3s), 0.09, 0.05 and 0.04 (12H, 8s).

Example 1

(5Z,11a,18E)-11,16-dihydroxy-9-oxo-17,17-propandiprost-5,13-dienoic acid : methyl ester



To a solution of the compound prepared in reference example 3 (330 mg) in acetonitrile (7 ml) was added pyridine (3 ml) and a 47% aqueous solution of hydrofluoric acid (6 ml). The reaction mixture was stirred at room temperature for 5 hours. The reaction mixture quenched by addition of water, extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium hydrogencarbonate and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 1 : 1) to give the compound of the present invention in the form of each stereoisomer on the 16-position, i.e. a less polar compound (55 mg) and a more polar compound (55 mg), having the following physical data.

TLC: Rf 0.37 (hexane : ethyl acetate = 2 : 3);
NMR (CDCl₃): δ 5.71 (1H, ddd, J=15.3, 7.6, 6.3 Hz), 5.54-5.26 (3H, m), 4.19-4.00 (1H, m), 3.67 (3H, s), 3.55 (1H, ddd, J=10.0, 2.4 Hz), 2.75 (1H, ddd, J=18.6, 7.2, 1.0 Hz), 2.65-2.69 (1H, br), 2.50-1.50 (19H, m), 2.32 (2H, t, J=7.5 Hz), 1.50-1.20 (3H, m), 0.94 (3H, t, J=6.9 Hz).


more polar

TLC: Rf 0.29 (hexane : ethyl acetate = 2 : 3);
NMR (CDCl₃): δ 5.69 (1H, ddd, J=15.4, 8.2, 5.4 Hz), 5.49-5.25 (3H, m), 4.12-3.98 (1H, m), 3.67 (3H, s), 3.65-3.20 (1H, br), 3.55 (1H, ddd, J=10.2, 2.4 Hz), 2.74 (1H, ddd, J=18.4, 7.4, 1.0 Hz), 2.50-1.50 (19H, m), 2.31 (2H, t, J=7.3 Hz), 1.50-1.20 (3H, m), 0.94 (3H, t, J=6.9 Hz).

Example 1(1)-(12)


By the same procedure as provided in example 1, using the compound prepared in reference example 10 or reference example 11, compounds of the present invention having the following physical data were obtained.

Example 1(1)

(5Z,11 α ,16RS)-11,16-dihydroxy-9-oxo-17,17-propanoprost-5-ene-13-ynoic acid - methyl ester

TLC: Rf 0.57 (hexane : ethyl acetate = 1 : 2);
NMR (CDCl₃) : δ 5.54-5.31 (2H, m), 4.39-4.27 (1H, m), 3.70-3.63 (1H, m), 3.67 (3H, s), 3.40-3.30 (1H, brs), 2.75 (1H, dd, J=18.4, 7.2 Hz), 2.72-1.20 (24H, m), 0.93 (3H, t, J=7.0 Hz).

Example 1(2)

(11 α ,13E)-11,16-dihydroxy-9-oxo-17,17-propanoprost-13-ene-5-ynoic acid - methyl ester


TLC: Rf 0.53 (hexane : ethyl acetate = 1 : 2);
NMR (CDCl₃) : δ 5.80 (1H, ddd, J=15.4, 7.6, 6.2 Hz), 5.52 (1H, dd, J=15.4, 8.2 Hz), 4.22-4.06 (1H, m), 3.68 (3H, s), 3.59 (1H, dd, J=9.8, 2.8 Hz), 2.90-2.55 (3H, m), 2.50-1.20 (21H, m), 2.43 (2H, t, J=7.6 Hz), 0.94 (3H, t, J=6.8 Hz).

more polar

TLC: Rf 0.24 (hexane : ethyl acetate = 1 : 2);
NMR (CDCl₃) : δ 5.78 (1H, ddd, J=15.4, 8.2, 5.4 Hz), 5.46 (1H, dd, J=15.4, 8.6 Hz), 4.19-4.03 (1H, m), 3.68 (3H, s), 3.58 (1H, dd, J=10.0, 2.2 Hz), 2.90-2.55 (3H, m), 2.50-1.20 (21H, m), 2.43 (2H, t, J=7.4 Hz), 0.94 (3H, t, J=6.8 Hz).

Hz).

Example 2

(5Z,11 α ,16RS)-11,16-dihydroxy-9-oxo-17,17-propanoprost-5-enoic acid - methyl ester

By the same procedure as provided in reference example 3 \rightarrow example 1, using the compound prepared in reference example 6, compound of the present invention having the following physical data was obtained.


mixture

TLC: Rf 0.34 (hexane : ethyl acetate = 1 : 2);
NMR (CDCl₃) : δ 5.51-5.28 (2H, m), 4.28-4.16 (1H, m), 3.67 (3H, s), 3.55-3.50 (1H, m), 2.68 (1H, ddd, J=19, 7, 3 Hz), 2.50-1.20 (25H, m), 2.33 (2H, t, J=7 Hz), 0.93 (3H, t, J=7 Hz).

Example 3-(g)

By the same procedure as provided in reference example 1 \rightarrow reference example 2 \rightarrow reference example 3 \rightarrow example 1, using corresponding acetylene derivatives instead of (4RS)-5,5-propanocyclo-1-yn-4-ol as starting material in reference example 1, compounds of the present invention having the following physical data were obtained.

Example 3

(5Z,11 α ,13E)-11,16-dihydroxy-20-methyl-9-oxo-17,17-propanoprost-5,13-dienoic acid - methyl ester

less polar

TLC: Rf 0.32 (hexane : ethyl acetate = 1 : 1);

NMR (CDCl₃): δ 5.71 (1H, ddd, J=15, 8, 6 Hz), 5.52-5.27 (3H, m), 4.17-4.03 (1H, m), 3.67 (3H, s), 3.54 (1H, dd, J=10, 2 Hz), 2.75 (1H, dd, J=19, 8 Hz), 2.50-1.90 (9H, m), 2.30 (2H, t, J=7 Hz), 1.90-1.20 (14H, m), 0.90 (3H, t, J=7 Hz).


more polar

TLC: Rf 0.28 (hexane : ethyl acetate = 1 : 1);

NMR (CDCl₃): δ 5.71 (1H, ddd, J=15, 8, 6 Hz), 5.50-5.27 (3H, m), 4.17-4.00 (1H, m), 3.66 (3H, s), 3.56 (1H, dd, J=10, 2 Hz), 2.74 (1H, dd, J=17, 6 Hz), 2.48-1.20 (23H, m), 2.30 (2H, t, J=7 Hz), 0.92 (3H, t, J=7 Hz).

Example 3(1)

(5Z,11α,18E)-11,16-dihydroxy-20-ethyl-9-oxo-17,17-propanoprost-5,13-dienoic acid : methyl ester



less polar

TLC: Rf 0.31 (hexane : ethyl acetate = 1 : 1);

NMR (CDCl₃): δ 5.71 (1H, ddd, J=15, 8, 6 Hz), 5.52-5.27 (3H, m), 4.15-4.02 (1H, m), 3.67 (3H, s), 3.54 (1H, dd, J=10, 2 Hz), 2.75 (1H, dd, J=19, 8 Hz), 2.50-1.90 (9H, m), 2.32 (2H, t, J=7 Hz), 1.90-1.20 (16H, m), 0.90 (3H, t, J=7 Hz).


more polar

TLC: Rf 0.27 (hexane : ethyl acetate = 1 : 1);

NMR (CDCl₃): δ 5.72 (1H, ddd, J=15, 8, 6 Hz), 5.49-5.27 (3H, m), 4.12-3.99 (1H, m), 3.66 (3H, s), 3.55 (1H, dd, J=10, 2 Hz), 2.75 (1H, dd, J=19, 8 Hz), 2.50-1.90 (9H, m), 2.33 (2H, t, J=7 Hz), 1.90-1.10 (16H, m), 0.90 (3H, t, J=7 Hz).

Example 3(2)

(5Z,11α,18E)-20-chloro-11,16-dihydroxy-9-oxo-17,17-propanoprost-5,13-dienoic acid : methyl ester



less polar

TLC: Rf 0.24 (hexane : ethyl acetate = 1 : 2);

NMR (CDCl₃): δ 5.70 (1H, ddd, J=15, 8, 6 Hz), 5.53-5.26 (3H, m), 4.17-4.03 (1H, m), 3.67 (3H, s), 3.59-3.53 (3H, m), 2.76 (1H, dd, J=19, 8 Hz), 2.50-1.45 (21H, m), 2.30 (2H, t, J=7 Hz).


more polar

TLC: Rf 0.18 (hexane : ethyl acetate = 1 : 2);

NMR (CDCl₃): δ 5.70 (1H, ddd, J=15, 8, 6 Hz), 5.50-5.28 (3H, m), 4.17-4.00 (1H, m), 3.66 (3H, s), 3.59-3.53 (3H, m), 2.74 (1H, dd, J=19, 7 Hz), 2.50-1.50 (21H, m), 2.30 (2H, t, J=7 Hz).

Example 3(3)

(5Z,11α,18E)-11,16-dihydroxy-9-oxo-18-phenyl-17,17-propano-19,20-dinoprosta-5,13-dienoic acid : methyl ester



less polar

TLC: Rf 0.29 (hexane : ethyl acetate = 1 : 2);


NMR (CDCl₃): δ 7.33-7.20 (5H, m), 5.70 (1H, ddd, J=15, 8, 6 Hz), 5.54-5.27 (3H, m), 4.18-4.03 (1H, m), 3.66 (3H, s), 3.57 (1H, dd, J=10, 2 Hz), 2.92 (1H, d, J=13 Hz), 2.76 (1H, dd, J=19, 7 Hz), 2.65 (1H, d, J=13 Hz), 2.50-1.45 (17H, m), 2.30 (2H, t, J=7 Hz).

more polar

TLC: Rf 0.21 (hexane : ethyl acetate = 1 : 2);
 NMR (CDCl₃): δ 7.96-7.18 (5H, m), 5.70 (1H, ddd, J=15.8, 6 Hz), 5.49-5.26 (3H, m), 4.18-3.98 (1H, m), 3.65 (3H, s), 3.57 (1H, dd, J=10.2 Hz), 2.91 (1H, d, J=14 Hz), 2.73 (1H, ddd, J=18.4, 7.4 Hz), 2.66 (1H, d, J=14 Hz), 2.50-1.45 (17H, m), 2.30 (2H, t, J=7 Hz).

Example 3(4)

10 (5Z,11α,13E)-11,16-dihydroxy-9-oxo-17,17-propanoprostas-5,13,19-trienic acid • methyl ester



less polar


TLC: Rf 0.44 (hexane : ethyl acetate = 1 : 2);
 NMR (CDCl₃): δ 5.95 (1H, ddd, J=17.0, 10.0, 7.4 Hz), 5.71 (1H, ddd, J=15.4, 7.7, 5.8 Hz), 5.60-5.25 (8H, m), 5.20-5.05 (2H, m), 4.18-4.02 (1H, m), 3.67 (3H, s), 3.56 (1H, dd, J=9.6, 2.0 Hz), 2.76 (1H, ddd, J=18.3, 7.3, 1.4 Hz), 2.50-1.55 (21H, m), 2.32 (2H, t, J=7.5 Hz).

more polar

TLC: Rf 0.34 (hexane : ethyl acetate = 1 : 2);
 NMR (CDCl₃): δ 5.95 (1H, ddd, J=17.2, 10.0, 7.4 Hz), 5.70 (1H, ddd, J=15.4, 7.6, 5.6 Hz), 5.57-5.25 (9H, m), 5.20-5.05 (2H, m), 4.14-3.98 (1H, m), 3.67 (3H, s), 3.56 (1H, dd, J=10.2, 2.3 Hz), 3.00-2.70 (1H, br), 2.74 (1H, ddd, J=18.2, 7.4, 1.4 Hz), 2.50-1.55 (20H, m), 2.32 (2H, t, J=7.5 Hz).

Example 3(5)

15 (5Z,11α,13E)-11,16-dihydroxy-20-methyl-9-oxo-17,17-propanoprostas-5,13-diene-19-ynoic acid • methyl ester



less polar


TLC: Rf 0.43 (hexane : ethyl acetate = 1 : 2);
 NMR (CDCl₃): δ 5.83-5.68 (1H, m), 5.55-5.25 (3H, m), 4.18-4.00 (1H, m), 3.75-3.60 (1H, m), 3.67 (3H, s), 2.75 (1H, ddd, J=18.4, 7.4, 1.4 Hz), 2.50-1.55 (21H, m), 2.32 (2H, t, J=7.4 Hz), 1.80 (3H, t, J=2.6 Hz).

more polar

TLC: Rf 0.33 (hexane : ethyl acetate = 1 : 2);
 NMR (CDCl₃): δ 5.72 (1H, ddd, J=15.0, 7.8, 5.8 Hz), 5.52-5.25 (3H, m), 4.15-3.98 (1H, m), 3.75-3.62 (1H, m), 3.67 (3H, s), 2.74 (1H, ddd, J=18.4, 7.2, 1.4 Hz), 2.50-1.50 (21H, m), 2.32 (2H, t, J=7.2 Hz), 1.80 (3H, t, J=2.6 Hz).

Example 3(6)

20 (5Z,11α,13E)-17,17-bulano-11,16-dihydroxy-9-oxoprostas-5,18-dienic acid • methyl ester



less polar

TLC: Rf 0.43 (hexane : ethyl acetate = 2 : 3);
 NMR (CDCl₃): δ 5.71 (1H, ddd, J=15.2, 7.8, 5.7 Hz), 5.54-5.25 (3H, m), 4.14-4.01 (1H, m), 3.67 (3H, s), 3.47 (1H, dd, J=10.2, 2.0 Hz), 2.75 (1H, ddd, J=18.4, 7.4, 1.0 Hz), 2.50-1.80 (10H, m), 2.32 (2H, t, J=7.4 Hz), 1.80-1.50 (9H, m), 1.50-1.20 (6H, m), 0.90 (3H, t, J=6.8 Hz).


more polar

TLC: Rf 0.34 (hexane : ethyl acetate = 2 : 3);

NMR (CDCl₃) : δ 5.67 (1H, ddd, J=15.2, 8.2, 5.2 Hz), 5.48-5.28 (3H, m), 4.12-3.96 (1H, m), 3.70-3.40 (1H, br), 3.67 (3H, s), 3.48 (1H, dd, J=10.2, 2.0 Hz), 2.75 (1H, ddd, J=18.4, 7.6, 1.0 Hz), 2.50-1.80 (10H, m), 2.31 (2H, t, J=7.5 Hz), 1.80-1.50 (8H, m), 1.50-1.20 (8H, m), 0.90 (3H, t, J=6.6 Hz).

Example 3(7)

(5Z,11α,18E)-11,16-dihydroxy-9-oxo-17,17-pentaproposta-5,13-dienoic acid • methyl ester



less polar

TLC: Rf 0.47 (hexane : ethyl acetate = 2 : 3);

NMR (CDCl₃) : δ 5.71 (1H, ddd, J=15.4, 8.0, 5.6 Hz), 5.53-5.28 (3H, m), 4.16-4.01 (1H, m), 3.67 (3H, s), 3.47 (1H, dd, J=10.6, 2.0 Hz), 2.76 (1H, ddd, J=18.6, 7.4, 1.2 Hz), 2.50-2.00 (10H, m), 2.32 (2H, t, J=7.4 Hz), 2.00-1.15 (17H, m), 0.91 (3H, t, J=6.5 Hz).


more polar

TLC: Rf 0.38 (hexane : ethyl acetate = 2 : 3);

NMR (CDCl₃) : δ 5.69 (1H, ddd, J=15.4, 8.0, 5.6 Hz), 5.48-5.25 (3H, m), 4.12-3.96 (1H, m), 3.67 (3H, s), 3.60-3.00 (1H, br), 3.47 (1H, dd, J=10.5, 1.7 Hz), 2.75 (1H, ddd, J=18.4, 7.4, 1.0 Hz), 2.50-1.95 (10H, m), 2.31 (2H, t, J=7.4 Hz), 1.80-1.15 (16H, m), 0.91 (3H, t, J=6.7 Hz).

Example 3(6)

(5Z,11α,13E)-18-cyclohexyl-11,16-dihydroxy-9-oxo-17,17-propano-18,20-dinorprosta-5,13-dienoic acid • methyl ester



less polar

TLC: Rf 0.40 (hexane : ethyl acetate = 2 : 3);

NMR (CDCl₃) : δ 5.74 (1H, ddd, J=15.2, 8.0, 6.0 Hz), 5.60-5.25 (3H, m), 4.18-4.02 (1H, m), 3.67 (3H, s), 3.67-3.58 (1H, m), 2.76 (1H, dd, J=19.2, 7.8 Hz), 2.60-1.95 (13H, m), 2.33 (2H, t, J=7.6 Hz), 1.95-1.45 (12H, m), 1.45-0.85 (7H, m).


more polar

TLC: Rf 0.35 (hexane : ethyl acetate = 2 : 3);

NMR (CDCl₃) : δ 5.72 (1H, ddd, J=15.4, 8.2, 5.2 Hz), 5.50-5.25 (3H, m), 4.14-3.98 (1H, m), 3.67 (3H, s), 3.61 (1H, dd, J=10.2, 2.0 Hz), 3.49 (1H, br), 2.74 (1H, ddd, J=18.4, 7.4, 1.0 Hz), 2.60-1.95 (12H, m), 2.32 (2H, t, J=7.6 Hz), 1.95-1.45 (12H, m), 1.45-0.85 (7H, m).

Example 3(9)

(5Z,11α,18E)-11,16-dihydroxy-9-oxo-17,17-propano-20-norprosta-5,13-dienoic acid • methyl ester



less polar

TLC: Rf 0.35 (hexane : ethyl acetate = 1 : 2);


NMR (CDCl₃) : δ 5.71 (1H, ddd, J=15.8, 8.6 Hz), 5.52-5.24 (3H, m), 4.15-4.03 (1H, m), 3.67 (3H, s), 3.56 (1H, dd, J=10.2 Hz), 2.75 (1H, ddd, J=19.7, 1 Hz), 2.50-1.35 (19H, m), 2.34 (2H, t, J=7.6 Hz), 0.92 (3H, t, J=7.6 Hz).

more polar

TLC: Rf 0.28 (hexane : ethyl acetate = 1 : 2);
 NMR (CDCl₃): δ 5.71 (1H, ddd, J=15, 8, 6 Hz), 5.40-5.28 (3H, m), 4.12-3.99 (1H, m), 3.66 (3H, s), 3.56 (1H, dd, J=10, 2 Hz), 2.73 (1H, ddd, J=19, 7, 1 Hz), 2.48-1.47 (19H, m), 2.34 (2H, t, J=7 Hz), 0.92 (3H, t, J=7 Hz).

Example 4

(5Z,11α,13E)-11,16-dihydroxy-20-methyl-9-oxo-17,17-propanoprost-5,13-dienoic acid



To the mixture of the less polar compound prepared in example 1 (55 mg) in ethanol (0.4 ml) and phosphate buffer (pH 7.4, 4 ml) was added PLE (pig liver esterase, 20 μl) at room temperature. The reaction mixture was stirred for 3 hours. The reaction mixture was quenched by addition of a saturated aqueous solution of ammonium sulfate, extracted with ethyl acetate. The extract was washed with 1N aqueous solution of hydrochloric acid and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 1 : 1 → ethyl acetate) to give the present invention compound (53 mg) having the following physical data. By the same procedure as provided in the above method, using the more polar compound prepared in example 1, compound (29 mg) of the present invention having the following physical data were obtained.

less polar

TLC: Rf 0.41 (ethyl acetate : hexane = 16 : 8 : 1);
 NMR (CDCl₃): δ 5.74 (1H, dt, J=15.0, 6.0 Hz), 5.55-5.25 (3H, m), 4.08 (1H, q, J=7.5 Hz), 3.64 (1H, dd, J=10.5, 2.5 Hz), 2.75 (1H, dd, J=18.0, 7.5 Hz), 2.50-2.20 (7H, m), 2.20-1.20 (18H, m), 0.94 (3H, t, J=7.0 Hz).

more polar


TLC: Rf 0.36 (ethyl acetate : hexane = 16 : 8 : 1);
 NMR (CDCl₃): δ 5.71 (1H, ddd, J=14.0, 8.0, 8.0 Hz), 5.54-5.30 (3H, m), 4.05 (1H, q, J=8.5 Hz), 3.61 (1H, dd, J=10.0, 2.5 Hz), 2.74 (1H, dd, J=19.0, 8.0 Hz), 2.50-2.20 (7H, m), 2.20-1.20 (18H, m), 0.95 (3H, t, J=6.5 Hz).

Example 4(1)-4(13)

By the same procedure as provided in example 4, using the compound prepared in example 3-3(9), example 2 or example 1(1)-(12), compounds of the present invention having the following physical data were obtained.

Example 4(1)

(5Z,11α,13E)-11,16-dihydroxy-20-methyl-9-oxo-17,17-propanoprost-5,13-dienoic acid



less polar


TLC: Rf 0.74 (ethyl acetate : acetic acid = 50 : 1);
 NMR (CDCl₃): δ 5.72 (1H, dt, J=18, 7 Hz), 5.52-5.31 (3H, m), 5.10-4.50 (3H, brs), 4.14-4.01 (1H, m), 3.60 (1H, dd, J=16, 2 Hz), 2.74 (1H, dd, J=18, 7 Hz), 2.45-1.15 (25H, m), 0.90 (3H, t, J=7 Hz).

more polar

TLC: Rf 0.87 (ethyl acetate : acetic acid = 50 : 1);
 NMR (CDCl₃): δ 5.90-4.80 (7H, m), 4.10-3.98 (1H, m), 3.56 (1H, d, J=9 Hz), 2.72 (1H, dd, J=18, 7 Hz), 2.47-1.15 (23H, m), 2.30 (2H, t, J=7 Hz), 0.90 (3H, t, J=7 Hz).

Example 4(2)

(5Z,11α,13E)-11,16-dihydroxy-20-ethyl-9-oxo-17,17-propanoprost-5,13-dienoic acid



less polar

TLC: Rf 0.80 (ethyl acetate : acetic acid = 50 : 1);
 NMR (CDCl₃): δ 5.72 (1H, dt, J=15, 7 Hz), 5.52-5.31 (3H, m), 5.60-4.40 (3H, brs), 4.14-4.01 (1H, m), 3.60 (1H, dd, J=11, 2 Hz), 2.74 (1H, dd, J=18, 8 Hz), 2.45-1.18 (25H, m), 2.34 (2H, t, J=7 Hz), 0.90 (3H, t, J=7 Hz).


more polar

TLC: Rf 0.75 (ethyl acetate : acetic acid = 50 : 1);

NMR (CDCl₃): δ 5.76-5.61 (1H, m), 5.48-5.32 (3H, m), 4.80-4.20 (3H, brs), 4.11-3.88 (1H, m), 3.59 (1H, dd, J=10, 1 Hz), 2.73 (1H, dd, J=18, 8 Hz), 2.45-1.15 (25H, m), 2.35 (2H, t, J=7 Hz), 0.90 (3H, t, J=7 Hz).

Example 4(3)

(5Z, 11 α , 13E)-20-chloro-1,16-dihydroxy-9-oxo-17,17-propanoprost-5,13-dienoic acid



less polar


TLC: Rf 0.50 (ethyl acetate : acetic acid, 50:1);
NMR (CDCl₃): δ 5.80-5.65 (1H, m), 5.54-5.38 (3H, m), 4.20-3.00 (3H, br), 4.17-4.02 (1H, m), 3.63 (1H, dd, J=10, 2 Hz), 3.56 (2H, t, J=6.2 Hz), 2.76 (1H, dd, J=17.8, 8.8 Hz), 2.46-1.48 (23H, m).

more polar

TLC: Rf 0.44 (ethyl acetate : acetic acid = 50 : 1);
NMR (CDCl₃): δ 5.68 (1H, dd, J=15, 7, 5 Hz), 5.50-5.28 (3H, m), 4.80-4.00 (3H, br), 4.12-3.98 (1H, m), 3.63-3.53 (3H, m), 2.74 (1H, dd, J=18, 7 Hz), 2.45-1.50 (21H, m), 2.30 (2H, t, J = 7 Hz).

Example 4(4)

(5Z, 11 α , 13E)-11,16-dihydroxy-9-oxo-18-phenyl-17,17-propano-19,20-dinoprosta-5,13-dienoic acid



less polar

TLC: Rf 0.52 (ethyl acetate : acetic acid = 50 : 1);
NMR (CDCl₃): δ 7.37-7.18 (5H, m), 5.72 (1H, dd, J=15, 7, 6 Hz), 5.54-5.40 (3H, m), 4.14-4.01 (1H, m), 3.67 (1H, dd, J=10, 2 Hz), 3.50-2.90 (3H, br), 2.90 (1H, dd, J=18 Hz), 2.75 (1H, dd, J=18, 8 Hz), 2.68 (1H, d, J=14 Hz), 2.47-


1.45 (17H, m), 2.31 (2H, t, J=7 Hz).

more polar

TLC: Rf 0.43 (ethyl acetate : acetic acid = 50 : 1);
NMR (CDCl₃): δ 7.37-7.18 (5H, m), 5.67 (1H, dd, J=15, 8, 6 Hz), 5.49-5.28 (3H, m), 5.20-4.60 (3H, br), 4.18-3.98 (1H, m), 3.62 (1H, br, J=10 Hz), 2.87 (1H, d, J=14 Hz), 2.73 (1H, dd, J=18, 8 Hz), 2.65 (1H, d, J=14 Hz), 2.45-1.42 (18H, m).

Example 4(5)

(5Z, 11 α , 13E)-11,16-dihydroxy-9-oxo-17,17-propanoprost-5,13-19-trienoic acid



less polar


TLC: Rf 0.28 (hexane : ethyl acetate : acetic acid = 1 : 2 : 0.03);
NMR (CDCl₃): δ 5.94 (1H, dd, J=17.0, 10.0, 7.4 Hz), 5.72 (1H, dd, J=15.0, 7.8, 6.2 Hz), 5.60-5.30 (3H, m), 5.20-5.05 (2H, m), 5.00-4.00 (3H, br), 4.16-4.00 (1H, m), 3.63 (1H, dd, J=10.2, 2.4 Hz), 2.75 (1H, dd, J=18.2, 7.4, 1.0 Hz), 2.50-1.60 (21H, m).

more polar

TLC: Rf 0.21 (hexane : ethyl acetate : acetic acid = 1 : 2 : 0.03);
NMR (CDCl₃): δ 5.94 (1H, dd, J=17.2, 10.2, 7.2 Hz), 5.66 (1H, dd, J=15.2, 8.0, 5.6 Hz), 5.53-5.25 (3H, m), 5.30-4.80 (3H, br), 5.20-5.00 (2H, m), 4.12-3.96 (1H, m), 3.58 (1H, dd, J=10.2, 1.8 Hz), 2.72 (1H, dd, J=18.2, 7.2 Hz), 2.50-1.80 (21H, m).

Example 4(5)

(5Z, 11α, 13E)-11, 16-dihydroxy-20-methyl-8-oxo-17, 17-propanoprost-5, 13-diene-19-ynoic acid



less polar


TLC: Rf 0.26 (hexane : ethyl acetate : acetic acid = 1 : 2 : 0.03);
 NMR (CDCl₃): δ 5.84-5.65 (1H, m), 5.59-5.32 (3H, m), 4.80-3.60 (3H, br), 4.18-4.00 (1H, m), 3.77 (1H, dd, J=10.0, 2.6 Hz), 2.78 (1H, dd, J=18.4, 7.4, 1.0 Hz), 2.50-1.60 (21H, m), 1.81 (3H, t, J=2.5 Hz).

more polar

TLC: Rf 0.20 (hexane : ethyl acetate : acetic acid = 1 : 2 : 0.03);
 NMR (CDCl₃): δ 5.71 (1H, dd, J=13.0, 7.6, 5.8 Hz), 5.52-5.28 (3H, m), 5.30-4.20 (3H, br), 4.13-3.95 (1H, m), 3.72 (1H, dd, J=10.2, 2.2 Hz), 2.74 (1H, dd, J=18.4, 7.4, 1.0 Hz), 2.50-1.60 (21H, m), 1.81 (3H, t, J=2.5 Hz).

Example 4(7)

(5Z, 11α, 13E)-17, 17-butano-11, 16-dihydroxy-9-oxoprost-5, 13-dienoic acid



less polar

TLC: Rf 0.33 (hexane : ethyl acetate : acetic acid = 2 : 3 : 0.05);
 NMR (CDCl₃): δ 5.82-5.65 (1H, m), 5.55-5.30 (3H, m), 5.40-4.60 (3H, br), 4.16-3.98 (1H, m), 3.55 (1H, dd, J=10.6, 2.0 Hz), 2.75 (1H, dd, J=18.0, 7.0 Hz), 2.50-1.90 (11H, m), 1.80-1.10 (14H, m), 0.90 (3H, t, J=6.4 Hz).


more polar

TLC: Rf 0.26 (hexane : ethyl acetate : acetic acid = 2 : 3 : 0.05);

NMR (CDCl₃): δ 5.75-5.57 (1H, m), 5.50-5.30 (3H, m), 5.80-4.80 (3H, br), 4.12-3.94 (1H, m), 3.51 (1H, d, J= 9.4 Hz), 2.73 (1H, dd, J=18.0, 7.0 Hz), 2.50-1.95 (11H, m), 1.80-1.10 (14H, m), 0.90 (3H, t, J= 6.4 Hz).

Example 4(8)

(5Z, 11α, 13E)-11, 16-dihydroxy-9-oxo-17, 17-pentanoprost-5, 13-dienoic acid



less polar


TLC: Rf 0.35 (hexane : ethyl acetate : acetic acid = 2 : 3 : 0.05);
 NMR (CDCl₃): δ 5.81-5.63 (1H, m), 5.55-5.30 (3H, m), 5.40-4.50 (3H, br), 4.15-3.98 (1H, m), 3.53 (1H, d, J= 10.2 Hz), 2.75 (1H, dd, J=18.2, 7.0 Hz), 2.50-1.90 (11H, m), 1.80-1.10 (16H, m), 0.90 (3H, t, J= 6.4 Hz).

more polar

TLC: Rf 0.28 (hexane : ethyl acetate : acetic acid = 2 : 3 : 0.05);
 NMR (CDCl₃): δ 5.75-5.57 (1H, m), 5.50-5.30 (3H, m), 5.80-5.00 (3H, br), 4.11-3.95 (1H, m), 3.50 (1H, d, J= 10.0 Hz), 2.73 (1H, dd, J=18.4, 7.0 Hz), 2.50-1.90 (11H, m), 1.80-1.10 (16H, m), 0.90 (3H, t, J= 6.4 Hz).

Example 4(9)

(5Z, 11α, 13E)-18-cyclohexyl-11, 16-dihydroxy-9-oxo-17, 17-propano-19, 20-dinoprost-5, 13-dienoic acid




less polar

TLC: Rf 0.36 (hexane : ethyl acetate : acetic acid = 1 : 2 : 0.03);
 NMR (CDCl₃): δ 5.75 (1H, dd, J=15.2, 7.4, 6.0 Hz), 5.55-5.30 (3H, m), 5.40-4.40 (3H, br), 4.17-4.02 (1H, m), 3.68 (1H, dd, J=10.2, 2.2 Hz), 2.78 (1H, dd, J=18.2, 7.0 Hz), 2.50-1.80 (14H, m), 1.90-1.40 (11H, m), 1.40-0.80 (7H, m).

more polar

TLC: Rf 0.26 (hexane : ethyl acetate : acetic acid = 1 : 2 : 0.03);
 NMR (CDCl₃) : δ 5.73 (1H, dd, J=15.0, 7.7, 6.1 Hz), 5.50-5.30 (3H, m), 4.80-3.60 (3H, br), 4.15-3.98 (1H, m), 3.66 (1H, dd, J=10.2, 2.0 Hz), 2.74 (1H, dd, J=18.2, 6.8 Hz), 2.50-1.90 (14H, m), 1.90-1.40 (11H, m), 1.40-0.80 (7H, m).

Example 4(10)

(5Z,11 α ,15E)-11,16-dihydroxy-9-oxo-17,17-propanoprost-5,13-dienoic acid


less polar

TLC: Rf 0.43 (ethyl acetate : acetic acid = 50 : 1);
 NMR (CDCl₃) : δ 5.73 (1H, dd, J=18, 8, 7 Hz), 5.53-5.38 (3H, m), 4.90-4.10 (3H, br), 4.14-4.02 (1H, m), 3.63 (1H, dd, J=10, 3 Hz), 2.75 (1H, dd, J=19, 8, 1 Hz), 2.45-1.30 (18H, m), 2.33 (2H, t, J=7 Hz), 0.92 (3H, t, J=7 Hz).

more polar

TLC: Rf 0.39 (ethyl acetate : acetic acid = 50 : 1);
 NMR (CDCl₃) : δ 5.71 (1H, dd, J=15, 8, 8 Hz), 5.49-5.29 (3H, m), 5.20-4.40 (3H, br), 4.11-3.98 (1H, m), 3.60 (1H, dd, J=10, 2 Hz), 2.73 (1H, dd, J=18, 7, 1 Hz), 2.45-1.35 (18H, m), 2.33 (2H, t, J=7 Hz), 0.92 (3H, t, J=7 Hz).


Example 4(11)

(5Z,11 α ,16R,S)-11,16-dihydroxy-9-oxo-17,17-propanoprost-5-enoic acid

TLC: Rf 0.62 (ethyl acetate : acetic acid = 50 : 1);

NMR (CDCl₃) : δ 5.50-5.20 (2H, m), 5.20-4.80 (3H, br), 4.20-4.10 (1H, m), 3.58-3.52 (1H, m), 2.75-2.61 (1H, dd, J=18, 7 Hz), 2.50-1.20 (25H, m), 2.32 (2H, t, J=7 Hz), 0.92 (3H, t, J=7 Hz).

Example 4(12)


(5Z,11 α ,16R,S)-11,16-dihydroxy-9-oxo-17,17-propanoprost-5-ene-13-ynoic acid

TLC: Rf 0.45 (ethyl acetate : acetic acid = 50 : 1);

NMR (CDCl₃) : δ 6.00-5.20 (3H, br), 5.50-5.30 (2H, m), 4.37-4.21 (1H, m), 3.75-3.65 (1H, m), 2.73 (1H, dd, J=18.2, 6.6 Hz), 2.70-1.20 (23H, m), 0.93 (3H, t, J=7.0 Hz).

Example 4(13)

(11a,13E)-11,16-dihydroxy-9-oxo-17,17-propaenoprostria-13-ene-5-ynoic acid



TLC: Rf 0.30 (hexane : ethyl acetate : acetic acid = 1 : 3 : 0.04);

NMR (CDCl₃): δ 5.83 (1H, dt, J=15.4, 6.8 Hz), 5.48 (1H, dt, J=15.4, 8.2 Hz), 5.50-4.50 (3H, br), 4.22-4.05 (1H, m), 3.60 (1H, dt, J=10.0, 2.4 Hz), 2.88-2.62 (3H, m), 2.49 (2H, t, J=7.1 Hz), 2.40-1.20 (19H, m), 0.94 (3H, t, J=6.7 Hz).

more polar

TLC: Rf 0.25 (hexane : ethyl acetate : acetic acid = 1 : 3 : 0.04);

NMR (CDCl₃): δ 6.00-4.80 (3H, br), 5.71 (1H, dt, J=15.0, 9.2, 4.4 Hz), 5.41 (1H, dt, J=15.0, 8.5 Hz), 4.20-4.03 (1H, m), 3.61 (1H, d, J=10.0 Hz), 2.88-2.65 (3H, m), 2.50 (2H, t, J=7.0 Hz), 2.40-1.20 (19H, m), 0.94 (3H, t, J=6.7 Hz).

Example 5

(5Z,11a,13E)-17,17-propaen-19,20-methano-11,16-dihydroxy-9-oxoprostria-5,13-dienoic acid - methyl ester



By the same procedure as provided in example 1, using the protected compound by TBS provided by the same procedure in reference example 1, reference example 2 or reference example 3, compounds of the present invention having the following physical data were obtained.

less polar

TLC: Rf 0.48 (hexane : ethyl acetate = 1 : 2);

NMR (CDCl₃): δ 5.73 (1H, dt, J=15.2, 7.8, 5.8 Hz), 5.54-5.28 (3H, m), 4.17-4.01 (1H, m), 3.74-3.63 (1H, m), 3.67

(3H, s), 2.75 (1H, ddd, J=18.4, 7.6, 1.0 Hz), 2.50-1.60 (19H, m), 2.32 (2H, t, J=7.6 Hz), 1.94 (1H, ddd, J=14.0, 6.8 Hz), 1.34 (1H, dt, J=14.0, 6.4 Hz), 0.90-0.68 (1H, m), 0.55-0.44 (2H, m), 0.16-0.05 (2H, m).

more polar

TLC: Rf 0.88 (hexane : ethyl acetate = 1 : 2);


NMR (CDCl₃): δ 5.70 (1H, ddd, J=15.4, 8.2, 5.8 Hz), 5.50-5.25 (3H, m), 4.14-3.98 (1H, m), 3.74-3.62 (1H, m), 3.67 (3H, s), 3.34 (1H, br), 2.74 (1H, ddd, J=18.4, 7.4, 1.0 Hz), 2.50-1.60 (19H, m), 2.31 (2H, t, J=7.4 Hz), 1.53 (1H, ddd, J=14.0, 6.8 Hz), 1.58 (1H, dt, J=14.0, 6.4 Hz), 0.90-0.68 (1H, m), 0.55-0.45 (2H, m), 0.16-0.08 (2H, m).

Example 5(1)-(5(7)

By the same procedure as provided in example 5, compounds of the present invention having the following physical data were obtained.

Example 5(1)

(5Z,11a,13E)-17,17-propaen-20,20-methylene-11,16-dihydroxy-9-oxoprostria-5,13-dienoic acid - methyl ester



less polar

TLC: Rf 0.49 (hexane : ethyl acetate = 1 : 2);


NMR (CDCl₃): δ 5.88 (1H, dt, J=17.0, 10.4, 6.5 Hz), 5.71 (1H, ddd, J=15.2, 7.8, 5.8 Hz), 5.55-5.25 (3H, m), 5.10-4.90 (2H, m), 4.18-4.01 (1H, m), 3.67 (3H, s), 3.57 (1H, dt, J=10.0, 2.6 Hz), 2.76 (1H, ddd, J=18.4, 7.4, 1.0 Hz), 2.50-1.40 (23H, m), 2.32 (2H, t, J=7.4 Hz).

more polar

TLC: Rf 0.40 (hexane : ethyl acetate = 1 : 2);

NMR (CDCl₃): δ 5.86 (1H, dt, J=17.2, 10.2, 6.4 Hz), 5.71 (1H, ddd, J=15.2, 8.0, 5.8 Hz), 5.50-5.25 (3H, m), 5.10-4.80 (2H, m), 4.14-3.98 (1H, m), 3.67 (3H, s), 3.57 (1H, dt, J=10.2, 2.4 Hz), 3.02 (1H, br), 2.74 (1H, ddd, J=18.4, 7.4, 1.0 Hz), 2.50-1.40 (22H, m), 2.32 (2H, t, J=7.5 Hz).

Example 5(2)

(5Z,11 α ,13E)-17,17-propano-20-methoxy-11,16-dihydroxy-9-oxaprostas-6,13-dienic acid - methyl ester


less polar

TLC: Rf 0.25 (hexane : ethyl acetate = 1 : 3);
 NMR (CDCl₃): δ 5.71 (1H, ddd, J=15.4, 7.4, 6.4 Hz), 5.55-5.25 (3H, m), 4.16-4.00 (1H, m), 3.67 (3H, s), 3.57 (1H, dd, J=9.6, 2.8 Hz), 3.48-3.30 (2H, m), 3.35 (3H, s), 2.75 (1H, ddd, J=18.4, 8.0, 1.0 Hz), 2.70 (1H, br), 2.50-1.45 (23H, m), 2.32 (2H, t, J=7.5 Hz).

more polar

TLC: Rf 0.17 (hexane : ethyl acetate = 1 : 3);
 NMR (CDCl₃): δ 5.69 (1H, ddd, J=15.2, 8.4, 5.6 Hz), 5.50-5.25 (3H, m), 4.15-3.98 (1H, m), 3.67 (3H, s), 3.56 (1H, dd, J=10.0, 2.2 Hz), 3.46-3.32 (2H, m), 3.35 (3H, s), 2.74 (1H, ddd, J=18.4, 7.4, 1.0 Hz), 2.50-1.45 (23H, m), 2.31 (2H, t, J=7.3 Hz).

Example 5(3)

(5Z,11 α ,13E)-17,17-propano-20-fluoro-11,16-dihydroxy-9-oxaprostas-5,13-dienic acid - methyl ester


less polar

TLC: Rf 0.31 (hexane : ethyl acetate = 1 : 2);
 NMR (CDCl₃): δ 5.71 (1H, ddd, J=15.4, 7.6, 5.8 Hz), 5.55-5.25 (3H, m), 4.47 (2H, dt, J=47.0, 5.2 Hz), 4.17-4.02 (1H, m), 3.67 (3H, s), 3.58 (1H, dd, J=10.0, 2.4 Hz), 2.76 (1H, ddd, J=18.6, 7.4, 1.2 Hz), 2.50-1.40 (23H, m), 2.32 (2H, t, J=7.3 Hz).

more polar

TLC: Rf 0.24 (hexane : ethyl acetate = 1 : 2);
 NMR (CDCl₃): δ 5.70 (1H, ddd, J=15.4, 8.2, 5.8 Hz), 5.52-5.25 (3H, m), 4.47 (2H, dt, J=46.8, 5.8 Hz), 4.14-3.88 (1H, m), 3.67 (3H, s), 3.58 (1H, dd, J=10.2, 2.2 Hz), 3.08 (1H, br), 2.74 (1H, ddd, J=18.4, 7.4, 1.0 Hz), 2.50-1.40 (23H, m), 2.32 (2H, t, J=7.5 Hz).

Example 5(4)

(5Z,11 α ,13E)-17,17-propano-19-methyl-11,16-dihydroxy-9-oxaprostas-5,13-dienic acid - methyl ester

less polar


TLC: Rf 0.45 (hexane : ethyl acetate = 1 : 2);
 NMR (CDCl₃): δ 5.73 (1H, ddd, J=15.2, 8.0, 6.0 Hz), 5.50-5.25 (3H, m), 4.17-4.02 (1H, m), 3.70-3.58 (1H, m), 3.67 (3H, s), 2.76 (1H, ddd, J=18.4, 7.6, 1.0 Hz), 2.50-1.60 (20H, m), 2.33 (2H, t, J=7.4 Hz), 1.58 (1H, dd, J=14.2, 6.8 Hz), 1.33 (1H, dd, J=14.2, 6.2 Hz), 0.92 (6H, d, J=6.8 Hz).

more polar

TLC: Rf 0.35 (hexane : ethyl acetate = 1 : 2);
 NMR (CDCl₃): δ 5.72 (1H, ddd, J=15.2, 8.2, 5.8 Hz), 5.50-5.25 (3H, m), 4.14-3.98 (1H, m), 3.70-3.59 (1H, m), 3.67 (3H, s), 3.24 (1H, br), 2.74 (1H, ddd, J=18.4, 7.6, 1.0 Hz), 2.50-1.60 (19H, m), 2.32 (2H, t, J=7.4 Hz), 1.58 (1H, dd, J=14.2, 6.8 Hz), 1.34 (1H, dd, J=14.2, 6.4 Hz), 0.92 (6H, d, J=6.8 Hz).

Example 5(5)

(5Z,11α,13E)-17,17-propano-11,16-dihydroxy-9-oxo-20-norprostria-5,13,18-trienic acid : methyl ester



20 less polar


TLC: Rf 0.30 (hexane : ethyl acetate = 1 : 2);
 NMR (CDCl₃) : δ 5.94 (1H, dd, J=17.2, 10.7 Hz), 5.69 (1H, ddd, J=15.2, 7.8, 8.0 Hz), 5.49-5.29 (3H, m), 5.22 (1H, dd, J=10.7, 1.8 Hz), 5.15 (1H, dd, J=17.2, 1.8 Hz), 4.19-4.01 (1H, m), 3.67 (3H, s), 3.60 (1H, dd, J=10.0, 2.3 Hz), 2.74 (1H, ddd, J=18.4, 7.4, 1.2 Hz), 2.45-1.60 (18H, m), 2.30 (2H, t, J=7.0 Hz).

more polar

TLC: Rf 0.22 (hexane : ethyl acetate = 1 : 2);
 NMR (CDCl₃) : δ 5.94 (1H, dd, J=17.0, 10.8 Hz), 5.67 (1H, ddd, J=15.2, 8.4, 5.8 Hz), 5.45-5.29 (3H, m), 5.23 (1H, dd, J=10.8, 1.8 Hz), 5.15 (1H, dd, J=17.0, 1.8 Hz), 4.19-3.97 (1H, m), 3.66 (3H, s), 3.59 (1H, dd, J=10.4, 2.2 Hz), 2.73 (1H, dd, J=18.2, 7.2 Hz), 2.44-1.60 (18H, m), 2.30 (2H, t, J=6.9 Hz).

Example 5(6)

(5Z,11α,13E)-17,17-propano-11,16-dihydroxy-9-oxo-19,20-dinorprostria-5,13-dienic acid : methyl ester




more polar

TLC: Rf 0.30 (hexane : ethyl acetate = 1 : 3);
 NMR (CDCl₃) : δ 5.71 (1H, ddd, J=15, 8, 6 Hz), 5.55-5.25 (3H, m), 4.18-4.02 (1H, m), 3.67 (3H, s), 3.56 (1H, dd, J=10, 2 Hz), 2.73 (1H, dd, J=19, 7, 1 Hz), 2.50-1.60 (21H, m), 1.15 (3H, s).

Example 5(7)

(5Z,11α,13E)-17,17-propano-11,16-dihydroxy-9-oxo-18,19,20-trinorprostria-5,13-dienic acid : methyl ester




20 more polar

TLC: Rf 0.25 (hexane : ethyl acetate = 1 : 3);
 NMR (CDCl₃) : δ 5.70 (1H, ddd, J=15, 8, 6 Hz), 5.54-5.26 (3H, m), 4.17-4.00 (1H, m), 3.68 (3H, s), 3.62-3.50 (1H, m), 2.74 (1H, ddd, J=18, 7, 1 Hz), 2.60-1.60 (22H, m).

Example 6

(5Z,11α,13E)-17,17-propano-18,20-methano-11,16-dihydroxy-9-oxoprostria-5,13-dienic acid



By the same procedure as provided in example 4, using each obtained the compound prepared in example 5, compounds of the present invention having the following physical data were obtained.

less polar

TLC: Rf 0.31 (hexane : ethyl acetate : acetic acid = 1 : 2 : 0.03);
 NMR (CDCl₃) : δ 5.83-5.68 (1H, m), 5.60-5.30 (3H, m), 5.40-4.20 (3H, br), 4.17-4.00 (1H, m), 3.77 (1H, dd, J=10.4, 2.2 Hz), 2.75 (1H, dd, J=18.4, 7.8 Hz), 2.50-1.60 (19H, m), 1.53 (1H, dd, J=14.2, 6.7 Hz), 1.35 (1H, dd, J=4.2, 6.4 Hz), 0.95-0.65 (1H, m), 0.60-0.45 (2H, m), 0.20-0.05 (2H, m).

more polar

TLC: Rf 0.26 (hexane : ethyl acetate : acetic acid = 1 : 2 : 0.03);


15Z, 11g, 13E)-17, 17-propano-20-methoxy-11, 16-dihydroxy-9-oxoprosta-5, 13-dienoic acid

Example 6(2)

15Z, 11g, 13E)-17, 17-propano-20-methoxy-11, 16-dihydroxy-9-oxoprosta-5, 13-dienoic acid

Example 6(2)

15Z, 11g, 13E)-17, 17-propano-20-methoxy-11, 16-dihydroxy-9-oxoprosta-5, 13-dienoic acid



ess polar

TLC: Rf 0.27 (ethyl acetate : acetic acid = 100 : 1);

Example 6(3)

TLC: Rf 0.30 (hexane : ethyl acetate : acetic acid = 1 : 3 : 0.04);

CC(F)CCCC[C@H]1C(=O)C[C@@H](C=C[C@H]2C=CC[C@@H](C2)C[C@@H](C1)O)O


TLC: Rf 0.30 (hexane : ethyl acetate : acetic acid = 1 : 3 : 0.04);

more polar

TLC: Rf 0.23 (hexane : ethyl acetate : acetic acid = 1 : 3 : 0.04);
 NMR (CDCl₃) : δ 5.68 (1H, ddd, J=15.5, 8.0, 5.5 Hz), 5.46 (1H, dd, J=15.5, 8.5 Hz), 5.50-4.50 (3H, br), 5.45-5.33 (2H, m), 4.55-4.48 and 4.46-4.38 (2H, m), 4.10-4.02 (1H, m), 3.61 (1H, dd, J=10.5, 2.0 Hz), 2.73 (1H, dd, J=18.0, 7.0 Hz), 2.43-2.25 (6H, m), 2.20 (1H, dd, J=18.0, 10.0 Hz), 2.15-1.95 (6H, m), 1.95-1.62 (9H, m), 1.57-1.48 (1H, m).

Example 6(4)

10 (5Z,11a,13E)-17,17-propeno-19-methyl-11,16-dihydroxy-9-oxopropsta-5,13-dienic acid



less polar


TLC: Rf 0.31 (hexane : ethyl acetate : acetic acid = 1 : 2 : 0.03);
 NMR (CDCl₃) : δ 5.75 (1H, dt, J=15.2, 6.4 Hz), 5.55-5.30 (3H, m), 5.40-4.40 (3H, br), 4.17-4.00 (1H, m), 3.70 (1H, dd, J=10.2, 2.0 Hz), 2.76 (1H, ddd, J=18.6, 7.4, 1.0 Hz), 2.50-1.50 (20H, m), 1.55 (1H, dd, J=14.2, 6.8 Hz), 1.33 (1H, dd, J=14.2, 6.2 Hz), 0.92 (6H, d, J=6.6 Hz).

more polar

TLC: Rf 0.24 (hexane : ethyl acetate : acetic acid = 1 : 2 : 0.03);
 NMR (CDCl₃) : δ 5.72 (1H, ddd, J=15.2, 8.0, 5.8 Hz), 5.55-5.25 (3H, m), 5.20-4.20 (3H, br), 4.14-3.98 (1H, m), 3.68 (1H, dd, J=10.0, 2.0 Hz), 2.74 (1H, ddd, J=18.0, 7.2, 1.0 Hz), 2.50-1.50 (20H, m), 1.55 (1H, dd, J=14.2, 7.2 Hz), 1.33 (1H, dd, J=14.2, 6.4 Hz), 0.92 (6H, d, J=6.4 Hz).

Example 6(5)

5 (5Z,11a,13E)-17,17-propeno-11,16-dihydroxy-9-oxo-20-norpropsta-5,13,18-trienic acid



less polar


TLC: Rf 0.36 (ethyl acetate : acetic acid = 50 : 1);
 NMR (CDCl₃) : δ 5.80 (1H, dd, J=17.2, 10.6 Hz), 5.70 (1H, ddd, J=15.2, 7.2, 5.8 Hz), 5.49-5.38 (3H, m), 5.24 (1H, dd, J=10.6, 1.4 Hz), 5.16 (1H, dd, J=17.2, 1.4 Hz), 4.20-3.20 (3H, br), 4.13-4.00 (1H, m), 3.68 (1H, dd, J=10.4, 2.4 Hz), 2.74 (1H, ddd, J=18.4, 7.4, 1.2 Hz), 2.43-1.60 (19H, m).

more polar

TLC: Rf 0.32 (ethyl acetate : acetic acid = 50 : 1);
 NMR (CDCl₃) : δ 5.83 (1H, dd, J=17.2, 10.6 Hz), 5.65 (1H, ddd, J=15.2, 8.2, 5.8 Hz), 5.28-5.15 (3H, m), 5.25 (1H, dd, J=10.6, 1.4 Hz), 5.16 (1H, dd, J=17.2, 1.4 Hz), 5.10-4.10 (3H, br), 4.08-3.95 (1H, m), 3.63 (1H, dd, J=10.6, 2.0 Hz), 2.70 (1H, ddd, J=19.2, 7.6, 1.1 Hz), 2.42-1.60 (19H, m).

Example 6(6)

35 (5Z,11a,13Z)-17,17-propeno-11,16-dihydroxy-9-oxopropsta-5,13-dienic acid



less polar


TLC: Rf 0.49 (hexane : ethyl acetate : acetic acid = 1 : 2 : 0.03);
 NMR (CDCl₃) : δ 6.00-4.00 (3H, br), 5.67 (1H, dt, J=5, 11 Hz), 5.46 (1H, t, J=11 Hz), 5.43-5.33 (2H, m), 4.08-4.00 (1H, m), 3.61 (1H, dd, J=10, 2 Hz), 2.83-2.72 (2H, m), 2.40-2.25 (3H, m), 2.33 (2H, t, J=7.5 Hz), 2.25 (1H, dd, J=19, 9.5 Hz), 2.15-2.03 (4H, m), 2.03-1.63 (8H, m), 1.60-1.53 (1H, m), 1.43-1.25 (3H, m), 0.95 (6H, t, J=7 Hz).

more polar

TLC: Rf 0.45 (hexane : ethyl acetate : acetic acid = 1 : 2 : 0.03);
 NMR (CDCl₃) : δ 6.69 (1H, dt, J=11, 8 Hz), 6.47-5.35 (3H, m), 5.00-3.00 (3H, br), 4.10-4.03 (1H, m), 3.64 (1H, dd, J=7, 3 Hz), 2.84-2.78 (2H, m), 2.43-1.95 (6H, m), 2.33 (2H, t, J=7 Hz), 2.28 (1H, dd, J=18.6, 9.5 Hz), 1.92-1.55 (7H, m), 1.45-1.30 (3H, m), 0.95 (3H, t, J=7 Hz).

Example 6(7)

10 (5Z,11α,13E)-17,17-propano-11,16-dihydroxy-9-oxo-19,20-dinorprosta-5,13-dienic acid




more polar

TLC: Rf 0.19 (hexane : ethyl acetate : acetic acid = 1 : 3 : 0.04);
 NMR (CDCl₃) : δ 6.00-4.00 (3H, br), 5.71 (1H, dd, J=15, 8, 6 Hz), 5.55-5.30 (3H, m), 4.15-3.95 (1H, m), 3.60 (1H, dd, J=10, 2 Hz), 2.79 (1H, ddd, J=18, 7, 1 Hz), 2.50-1.60 (19H, m), 1.15 (3H, s).

Example 6(8)

35 (5Z,11α,13E)-17,17-propano-11,16-dihydroxy-9-oxo-18,19,20-trinorprosta-5,13-dienic acid




more polar

TLC: Rf 0.16 (hexane : ethyl acetate : acetic acid = 1 : 3 : 0.04);
 NMR (CDCl₃) : δ 6.00-4.00 (3H, br), 5.70 (1H, ddd, J=15, 8, 6 Hz), 5.53-5.28 (3H, m), 4.13-3.96 (1H, m), 3.65-3.55 (1H, m), 2.74 (1H, ddd, J=18, 7, 1 Hz), 2.60-1.60 (20H, m).

Reference example 12

(5Z,13E)-17,17-propano-16-hydroxy-9-oxoprosta-5,10,13-trienic acid : methyl ester




To a solution of the compound prepared in example 1 (more polar; 95 mg) in THF (5 ml) was added copper chloride (40 mg) and 1N aqueous solution of hydrochloric acid (5 ml). The reaction mixture was stirred at 60 °C for 4 hours. The reaction mixture was quenched by addition of a saturated aqueous solution of sodium hydrogencarbonate, extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. To the residue dissolved into diethyl ether (5 ml) was added a solution of dimethylmethanethiosulfonic acid (hexane-ethyl acetate) to give the title compound (65 mg) having the following physical data.

TLC: Rf 0.68 (hexane : ethyl acetate = 1 : 1);
 NMR (CDCl₃) : δ 7.49 (1H, dd, J=6.0, 2.8 Hz), 6.16 (1H, dd, J=6.0, 2.2 Hz), 5.67-5.24 (4H, m), 3.67 (3H, s), 3.54 (1H, dd, J=9.8, 2.8 Hz), 3.25-3.19 (1H, m), 2.30-1.25 (20H, m), 2.32 (2H, t, J=6.8 Hz), 0.92 (3H, t, J=7.0 Hz).

Reference example 13

35 (5Z,13E)-17,17-propano-16-t-butyldimethylsilyloxy-9-oxoprosta-5,10,13-trienic acid : methyl ester




To a solution of the compound prepared in reference example 12 (60 mg) and 2,6-lutidine (116 μl) in anhydrous dichloromethane (5 ml) was added dropwise trifluoromethanesulfonic acid t-butyldimethylsilyl ester (180 μl) at 0 °C under an atmosphere of argon. The reaction mixture was stirred at 0 °C for 2 hours. The reaction mixture was quenched by addition of a saturated aqueous solution of sodium hydrogencarbonate, extracted with hexane (x2). The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane-ethyl acetate) to give the title compound (44 mg) having the following physical data.

TLC: Rf 0.53 (hexane : ethyl acetate = 4 : 1).

Reference example 14

6 (5Z,13E)-17,17-propano-16-*n*-butyldimethylsilyloxy-9-oxopropa-5,13-dienoic acid • methyl ester




To a suspension of lithium aluminum hydride (48 mg) in anhydrous THF (1 ml) was added a suspension of copper iodide (I) (190 mg) in THF-HMPA (1:1, 2 ml) at -78 °C under an atmosphere of argon. The mixture was stirred at same temperature for 30 min. To the mixture was added a solution of the compound prepared in reference example 13 (43 mg) in anhydrous THF (2 ml). The reaction mixture was stirred at same temperature for 30 min. To the reaction mixture was added a saturated aqueous solution of sodium ammonium, warmed up at room temperature, filtered. The precipitate was washed with ether. The water layer of the filtrate was extracted with ether. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (hexane-ethyl acetate) to give the title compound (2.5 mg) having the following physical data.

RI 0.41 (hexane : ethyl acetate = 4 : 1);

NMR (CDCl₃): δ 5.60–5.25 (4H, m), 3.66 (3H, s), 3.57 (1H, m), 2.50–1.20 (24H, m), 2.30 (2H, t, J = 6.8 Hz), 0.98–0.85 (12H, m), 0.03 (6H, s).

Example 7

(5Z,13E)-17,17-dimethoxy-9-oxooctadeca-5,13-dienoic acid • methyl ester



By the same procedure as provided in example 1, using the compound prepared in reference example 14, compounds of the present invention having the following physical data were obtained.

less polar

TLC: Rf 0.81 (hexane : ethyl acetate = 1 : 1):

NMR (CDCl_3): δ 5.58–5.33 (4H, m), 3.67 (3H, s), 3.51 (1H, dd, $J=10.2, 2.6$ Hz), 2.56–1.24 (25H, m), 2.33 (2H, t).

$J=7.6$ Hz), 0.94 (3H, t, $J=7.0$ Hz).


more polar

5 TLC: Rf 0.76(hexane : ethyl acetate = 1 : 1);

NMR (CDCl₃): δ 5.70–5.25 (4H, m), 3.67 (3H, s), 3.53 (1H, dd, $J=10.0, 2.4$ Hz), 2.58–1.22 (25H, m), 2.32 (2H, t, $J=7.6$ Hz), 0.94 (3H, t, $J=6.8$ Hz).

Example 8

(5Z,13E)-17,17-propano-16-hydroxy-9-oxoprosta-5,13-dienic acid



By the same procedure as provided in example 4, using the compound prepared in example 7, compounds of the present invention having the following physical data were obtained.

ess polar

TLC: Rf 0.74 (hexane : ethyl acetate : acetic acid = 100 : 100 : 1);


¹H NMR (CDCl₃): δ 5.58-5.37 (4H, m), 5.40-3.40 (2H, br), 3.60 (1H, dd, J=10.2, 2.2 Hz), 2.53-1.20 (24H, m), 2.30 (2H, t, J=6.8 Hz), 0.93 (3H, t, J=6.8 Hz).

more polar

TLC: Rf 0.71 (hexane : ethyl acetate : acetic acid = 100 : 100 : 1);

NMR (CDCl_3): δ 5.62-5.37 (4H, m), 5.60-3.20 (2H, br), 3.64-3.63 (1H, m), 2.55-1.20 (24H, m), 2.30 (2H, t, J=6.8 Hz), 0.94 (3H, t, J=6.8 Hz).

Example 9

(5Z,11 α ,13E)-17,17-propano-11-methoxy-16-hydroxy-9-oxo-19-methylnon-5,13-dienoic acid • methyl ester

To a solution of the compound prepared in example 1 (more polar: 78 mg) in ether (5 ml) was added silica gel (Kiesel gel) (4.7 g). To the mixture was added dropwise a solution of diazomethane in ether under cooling with ice. The suspension was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (Kiesel gel 7734, 20 g, hexane : ethyl acetate = 5 : 1 → 3 : 1) to give the present invention compound (more polar: 45 mg) having the following physical data.

more polar

RI 0.57 (hexane : ethyl acetate = 1 : 1);

NMR (CDCl₃) : δ 5.67 (1H, ddd, J=15.4, 7.6, 5.9 Hz), 5.51 (1H, dd, J=15.4, 7.8 Hz), 5.50-5.28 (2H, m), 3.77-3.63 (1H, m), 3.67 (3H, s), 3.53 (1H, dd, J=10.2, 2.4 Hz), 3.37 (3H, s), 2.76 (1H, ddd, J=18.6, 7.2, 1.2 Hz), 2.54 (1H, dt, J=11.8, 7.8 Hz), 2.45-1.20 (21H, m), 2.31 (2H, t, J=7.5 Hz), 0.94 (3H, t, J=6.9 Hz).

By the same reaction as provided in above method, using the less polar compound prepared in example 1, compound (less polar: 47 mg) of the present invention having the following physical data was obtained.

less polar


RI 0.66 (hexane : ethyl acetate = 1 : 1);

NMR (CDCl₃) : δ 5.74-5.28 (4H, m), 3.78-3.65 (1H, m), 3.67 (3H, s), 3.54 (1H, dd, J=10.0, 2.4 Hz), 3.36 (3H, s), 2.77 (1H, ddd, J=18.4, 7.0, 1.0 Hz), 2.55 (1H, dt, J=11.6, 7.4 Hz), 2.40-1.20 (21H, m), 2.32 (2H, t, J=7.4 Hz), 0.94 (3H, t, J=6.9 Hz).

Example 9(1)-8(4)

By the same procedure as provided in example 9, compounds of the present invention having the following physical data were obtained.

Example 9(1)


(5Z,11 α ,13E)-17,17-propano-11-methoxy-16-hydroxy-9-oxo-19-methylnon-5,13-dienoic acid • methyl ester

more polar

TLC: RI 0.72 (hexane : ethyl acetate = 1 : 1);

NMR (CDCl₃) : δ 5.79-5.25 (4H, m), 3.77-3.60 (2H, m), 3.66 (3H, s), 3.37 (3H, s), 2.76 (1H, ddd, J=18.4, 7.5, 1.2 Hz), 2.61-1.20 (21H, m), 2.33 (2H, t, J=6.9 Hz), 0.93 (3H, t, J=1.0 Hz), 0.90 (3H, t, J=1.0 Hz).

Example 9(2)

(5Z,11 α ,13E)-17,17-propano-11-methoxy-16-hydroxy-9-oxo-19,20-methanonon-5,13-dienoic acid • methyl ester

more polar

TLC: RI 0.63 (hexane : ethyl acetate = 1 : 1);

NMR (CDCl₃) : δ 5.77-5.23 (4H, m), 3.76-3.64 (2H, m), 3.66 (3H, s), 3.37 (3H, s), 2.76 (1H, ddd, J=18.4, 7.0, 1.2 Hz), 2.61-1.23 (20H, m), 2.33 (2H, t, J=6.9 Hz), 0.90-0.70 (1H, m), 0.55-0.45 (2H, m), 0.15-0.05 (2H, m).

Example 9(3)

(5Z,11α,13E)-17,17-propano-11-methoxy-16-hydroxy-9-oxo-20-norprostria-5,13-dienolic acid · methyl ester




more polar

TLC: Rf 0.58 (hexane : ethyl acetate = 1:1);
 NMR (CDCl₃): δ 5.75-5.27 (4H, m), 3.76-3.64 (1H, m), 3.54 (1H, dd, J=10.0, 2.4 Hz), 3.37 (3H, s), 2.76 (1H, dd, J=18.4, 7.0, 1.2 Hz), 2.60-1.35 (20H, m), 2.31 (2H, t, J=6.8 Hz), 0.92 (3H, t, J=7.2 Hz).

Example 9(4)

(5Z,11α,13E)-17,17-propano-11-methoxy-16-hydroxy-9-oxoprostria-5,13,19-trienolic acid · methyl ester




more polar

TLC: Rf 0.53 (hexane : ethyl acetate = 1:1);
 NMR (CDCl₃): δ 6.09-5.81 (1H, m), 5.75-5.23 (4H, m), 5.15-5.06 (2H, m), 3.76-3.64 (1H, m), 3.54 (1H, dd, J=10.4, 2.2 Hz), 3.37 (3H, s), 2.76 (1H, dd, J=18.4, 7.0, 1.4 Hz), 2.60-1.50 (20H, m), 2.31 (2H, t, J=6.8 Hz).

Example 10

(5Z,11α,13E)-17,17-propano-11-methoxy-16-hydroxy-9-oxoprostria-5,13-dienolic acid



By the same procedure as provided in example 4, using the compound prepared in example 9 (less polar or more polar), compounds of the present invention having the following physical data were obtained.

less polar

TLC: Rf 0.40 (hexane : ethyl acetate : methanol = 1:1:0.02);
 NMR (CDCl₃): δ 5.68 (1H, dd, J=15.4, 7.6, 5.4 Hz), 5.50 (1H, dd, J=15.4, 7.2 Hz), 5.50-5.30 (2H, m), 4.50-2.50 (2H, br), 3.76-3.63 (1H, m), 3.63 (1H, dd, J=10.4, 2.4 Hz), 3.38 (3H, s), 2.77 (1H, dd, J=18.2, 7.0, 1.0 Hz), 2.51 (1H, dt, J=11.4, 7.3 Hz), 2.40-1.20 (20H, m), 2.34 (2H, t, J=6.8 Hz), 0.94 (3H, t, J=6.7 Hz).


more polar

TLC: Rf 0.38 (hexane : ethyl acetate : methanol = 1:1:0.02);
 NMR (CDCl₃): δ 5.68 (1H, dd, J=15.4, 6.6, 6.0 Hz), 5.54 (1H, dd, J=15.4, 7.2 Hz), 5.50-5.30 (2H, m), 5.00-3.00 (2H, br), 3.77-3.63 (1H, m), 3.60 (1H, dd, J=10.0, 2.4 Hz), 3.37 (3H, s), 2.77 (1H, dd, J=18.2, 7.2, 1.2 Hz), 2.53 (1H, dt, J=11.2, 7.8 Hz), 2.42-1.20 (20H, m), 2.34 (2H, t, J=7.1 Hz), 0.94 (3H, t, J=6.8 Hz).

Example 10(1)-10(4)

By the same procedure as provided in example 10, compounds of the present invention having the following physical data were obtained.

Example 10(1)


(5Z,11 α ,13E)-17,17-propano-11-methoxy-16-hydroxy-19-methyl-9-oxoprost-5,13-dienic acid

more polar

TLC: Rf 0.28 (hexane : ethyl acetate = 1:1);

NMR (CDCl₃): δ 5.78-5.28 (4H, m), 5.00-4.00 (2H, br), 3.77-3.64 (2H, m), 3.37 (3H, s), 2.77 (1H, dd, J=18.4, 7.4 Hz), 2.60-1.22 (20H, m), 2.34 (2H, t, J=6.9 Hz), 0.93 (3H, d, J=1.2 Hz), 0.90 (3H, d, J=1.0 Hz).

Example 10(2)


(5Z,11 α ,13E)-17,17-propano-11-methoxy-16-hydroxy-9-oxo-19,20-methanoprost-5,13-dienic acid

more polar

TLC: Rf 0.29 (hexane : ethyl acetate = 1:1);

NMR (CDCl₃): δ 5.80-5.30 (4H, m), 3.79-3.64 (2H, m), 3.38 (3H, s), 2.77 (1H, dd, J=18.2, 7.2 Hz), 2.59-1.10 (23H, m), 0.85-0.70 (1H, m), 0.55-0.45 (2H, m), 0.15-0.05 (2H, m).

Example 10(3)


(5Z,11 α ,13E)-17,17-propano-11-methoxy-16-hydroxy-9-oxo-20-norprost-5,13-dienic acid

more polar

TLC: Rf 0.27 (hexane : ethyl acetate = 1:1);

NMR (CDCl₃): δ 5.78-5.30 (4H, m), 3.76-3.58 (2H, m), 3.60-2.60 (2H, br), 3.37 (3H, s), 2.77 (1H, dd, J=18.4, 7.0 Hz), 2.60-1.32 (19H, m), 2.33 (2H, t, J=7.0 Hz), 0.92 (3H, s), J=7.4 Hz).

Example 10(4)


(5Z,11 α ,13E)-17,17-propano-11-methoxy-16-hydroxy-9-oxoprost-5,13,19-trienic acid

more polar

TLC: Rf 0.25 (hexane : ethyl acetate = 1:1);

NMR (CDCl₃): δ 6.03-5.82 (1H, m), 5.77-5.30 (4H, m), 5.17-5.07 (2H, m), 4.40-1.40 (2H, br), 3.76-3.59 (2H, m), 3.37 (3H, s), 2.77 (1H, dd, J=18.4, 7.2, 1.2 Hz), 2.59-1.60 (19H, m), 2.33 (2H, t, J=7.0 Hz).

Reference example 15

(5Z,11 α ,13E)-17,17-propano-11,16-bis(butyldimethylsilyloxy)-9,9-methylenepenta-5,13-dienoic acid - methyl ester


To a stirred suspension of zinc powder (2.875 g) in THF (25 ml) was added dropwise dibromomethane (1.01 ml) at room temperature under an atmosphere of argon. After the reaction mixture cooled at -40 °C, to the mixture was slowly added dropwise titanium tetrachloride (1.13 ml). The mixture was stirred at 5 °C for 3 days. Nozaki-Lombardo reagent was obtained as a grayish suspension.

To a stirred solution of the compound prepared in reference example 3 (150 mg) in dichloromethane (3 ml) was added the above obtained Nozaki-Lombardo reagent (3 ml) at 0 °C. The reaction mixture was stirred at room temperature for 1.5 hours. The reaction mixture was quenched by addition of ice and a saturated aqueous solution of sodium chlorite, extracted with ether (x2). The extract was washed with water (x2), a saturated aqueous solution of hydrogen carbonate, extracted with ether (x2). The extract was washed with water (x2), a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (Merck-Kiesel gel 7734, 20 ml, ethyl acetate : hexane = 1 : 40) to give the title compound (120 mg) as a colorless oil having the following physical data.

TLC: Rf 0.47 (ethyl acetate : hexane = 1 : 20);

NMR (CDCl₃) : δ 5.65-5.15 (4H, m), 4.89 (1H, brs), 3.77 (1H, q, J = 7.5 Hz), 3.66 (3H, s), 3.56 (1H, t, J = 5.0 Hz), 2.60 (1H, dd, J = 16.5, 7.0 Hz), 2.40-1.15 (23H, m), 0.90 (9H, s), 1.00-0.80 (3H, m), 0.05 (9H, s), 0.02 (6H, s).

Example 11

(5Z,11 α ,13E)-17,17-propano-11,16-dihydroxy-9,9-methylenepenta-5,13-dienoic acid - methyl ester

By the same procedure as provided in example 1, using the compound prepared in reference example 15, compounds of the present invention having the following physical data were obtained.

less polar

TLC: Rf 0.39 (ethyl acetate : hexane = 1 : 2);


NMR (CDCl₃) : δ 5.70-5.30 (4H, m), 4.96 (1H, brs), 4.88 (1H, brs), 3.63 (1H, q, J = 7.5 Hz), 3.67 (9H, s), 3.52 (1H, dd, J = 10.0, 2.0 Hz), 2.76 (1H, dd, J = 16.0, 7.0 Hz), 2.40-1.20 (25H, m), 0.93 (3H, t, J = 7.0 Hz).

more polar

TLC: Rf 0.33 (ethyl acetate : hexane = 1 : 2);

NMR (CDCl₃) : δ 5.70-5.30 (4H, m), 4.96 (1H, brs), 4.88 (1H, brs), 3.62 (1H, q, J = 7.0 Hz), 3.70 (9H, s), 3.53 (1H, dd, J = 10.0, 2.5 Hz), 2.75 (1H, dd, J = 16.0, 7.0 Hz), 2.40-1.20 (25H, m), 0.94 (3H, t, J = 7.0 Hz).

Example 12

(5Z,11 α ,13E)-17,17-propano-11,16-dihydroxy-9,9-methylenepenta-5,13-dienoic acid

By the same procedure as provided in example 4, using the compound prepared in example 11, compounds of the present invention having the following physical data were obtained.

less polar

TLC: Rf 0.52 (ethyl acetate : hexane : acetic acid = 9 : 10 : 1);


NMR (CDCl₃) : δ 5.70-5.30 (4H, m), 4.98 (1H, brs), 4.89 (1H, brs), 3.82 (1H, q, J = 8.5 Hz), 3.61 (1H, dd, J = 10, 2.5 Hz), 2.74 (1H, dd, J = 15.5, 7.0 Hz), 2.40-1.20 (25H, m), 0.93 (3H, t, J = 7.0 Hz).

more polar

TLC: Rf 0.52 (ethyl acetate : hexane : acetic acid = 9 : 10 : 1);

NMR (CDCl₃) : δ 5.70-5.30 (4H, m), 4.96 (1H, brs), 4.88 (1H, brs), 3.81 (1H, q, J = 6.5 Hz), 3.59 (1H, dd, J = 10, 2.5 Hz), 2.78 (1H, dd, J = 16.0, 7.0 Hz), 2.40-1.20 (25H, m), 0.94 (3H, t, J = 7.0 Hz).

Example 13

(5Z,11 α ,13E)-17,17-propano-11,16-dihydroxy-9-oxopenta-5,13-dienic acid amide

To a stirred solution of the compound prepared in example 4 (less polar; 42 mg) in dichloromethane (1 ml) was added triethylamine (81 mg) and isobutyl chloroformate (60 mg) at 0 °C. After the mixture was stirred for 30 min, to the mixture was added ammonia in water solution (0.5 ml). The reaction mixture was stirred for 10 min. The reaction mixture was quenched by addition of 1N aqueous solution of hydrochloric acid, extracted with ethyl acetate (x3). The extract was washed with water (x2), 1N aqueous solution of hydrochloric acid (x2) and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (Merck Kiesel gel 7734, 5 ml, ethyl acetate : hexane = 3 : 2 → MeOH : CHCl₃ = 1 : 19 → 1 : 9) to give the present invention compound (32 mg) as a pale yellow oil having the following physical data.

less polar


TLC: Rf 0.52 (methanol : chloroform = 1 : 9);
NMR (CDCl₃): δ 5.90-5.20 (6H, m), 4.10 (1H, q, J=9.0 Hz), 3.55 (1H, d, J=6.0 Hz), 2.73 (1H, dd, J=11.0, 7.5 Hz), 2.75-2.55 (1H, m), 2.55-1.20 (24H, m), 0.94 (3H, t, J=6.5 Hz).

By the same procedure as provided in above example, using the compound prepared in example 4 (more polar), compound of the present invention having the following physical data was obtained.

more polar

TLC: Rf 0.52 (methanol : chloroform = 1 : 9);
NMR (CDCl₃): δ 5.90-5.80 (2H, m), 5.60-5.20 (4H, m), 4.07 (1H, q, J=6.5 Hz), 3.55 (1H, dd, J=10.0, 2.0 Hz), 3.04 (1H, brs), 2.74 (1H, dd, J=18.0, 7.0, 1.0 Hz), 2.75-2.50 (1H, m), 2.50-1.20 (28H, m), 0.94 (3H, t, J=7.0 Hz).

Reference example 16


(5Z,9 α ,11 α ,13E)-17,17-propano-11,16-bis(t-butyldimethylsilyloxy)-9-hydroxyprosta-5,13-dienic acid methyl ester

To a solution of (5Z,11 α ,13E)-17,17-propano-11,16-bis(t-butyldimethylsilyloxy)-9-oxopenta-5,13-dienic acid methyl ester (740 mg), the compound prepared in reference example 3) in THF (20 ml) was added dropwise L-Selectride (1.75 ml; 1.0 M in THF solution) at -78 °C under an atmosphere of argon. After the mixture was stirred at same temperature for 30 min, to the solution was added dropwise a 30% aqueous solution of hydrogen peroxide (1 ml) at same temperature. The reaction mixture was warmed up to 0 °C. The reaction mixture was quenched by addition of 2N aqueous solution of hydrochloric acid (1 ml), extracted with ethyl acetate. The extract was washed with water and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (Merck Kiesel gel 7734, 30 g, hexane : ethyl acetate = 9 : 1) to give the title compound (558 mg) as a pale yellow oil having the following physical data.

TLC: Rf 0.35 (hexane : ethyl acetate = 9 : 1);

NMR (CDCl₃): δ 5.60-5.10 (4H, m), 4.15-3.90 (2H, m), 3.66 (3H, s), 3.55 (1H, t, J=5 Hz), 2.70-2.50 (1H, m), 2.40-1.20 (24H, m), 1.00-0.80 (21H, m), 0.10-0.00 (12H, m).

Reference example 17


(5Z,9 α ,11 α ,13E)-17,17-propano-11,16-bis(t-butyldimethylsilyloxy)-9-acetyloxyprosta-5,13-dienic acid methyl ester

To a solution of the compound prepared in reference example 16 (518 mg) in pyridine (1 ml) was added acetic anhydride (0.15 ml) and dimethylaminopyridine (catalytic amount). The reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched by addition of water, extracted with ethyl acetate. The extract was washed with dilute hydrochloric acid, water and a saturated aqueous solution of sodium chloride, successively, dried, filtered, and concentrated to give the title compound having the following physical data.

TLC: Rf 0.42 (hexane : ethyl acetate = 9 : 1).

Reference example 18

(5Z,9a,11a,13E)-17,17-propeno-11,16-bis(2-ethoxyprop-1-en-1-yl)-9-ethoxyprosta-5,13-diene acid : methyl ester



To a solution of the compound prepared in reference example 17 in acetonitrile (10 ml) was added dropwise 48% aqueous solution of hydrofluoric acid (0.5 ml) under cooling with ice. The reaction mixture was stirred at room temperature for 1.5 hours. The reaction mixture was quenched by addition of a saturated aqueous solution of sodium hydrogencarbonate, extracted with ethyl acetate. The extract was washed with a saturated aqueous solution of sodium hydrogencarbonate and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by Lobar column chromatography (size B, hexane : ethyl acetate = 2 : 3) to give the title two compounds (less polar: 142 mg, more polar: 149 mg) having the following physical data.

less polar

TLC: Rf 0.30 (hexane : ethyl acetate = 1 : 1);

NMR (CDCl₃): δ 5.65 (1H, ddd, J=15.0, 7.8, 6.0 Hz), 5.45-5.30 (3H, m), 5.15-5.05 (1H, m), 4.00-3.85 (1H, m), 3.67 (3H, s), 3.55 (1H, dd, J=10.0, 2.4 Hz), 2.98-2.40 (1H, m), 2.40-1.30 (23H, m), 2.31 (2H, t, J=7.4 Hz), 2.08 (3H, s), 0.94 (3H, t, J=7.2 Hz).


more polar

TLC: Rf 0.28 (hexane : ethyl acetate = 1 : 1);

NMR (CDCl₃): δ 5.65 (1H, ddd, J=14.8, 8.0, 6.2 Hz), 5.43-5.25 (3H, m), 5.15-5.05 (1H, m), 3.85-3.82 (1H, m), 3.67 (3H, s), 3.55 (1H, dd, J=10.0, 2.4 Hz), 2.60-2.40 (1H, m), 2.40-1.20 (23H, m), 2.30 (2H, t, J=7.4 Hz), 2.06 (3H, s), 0.94 (3H, t, J=6.7 Hz).

Reference example 19

(5Z,9a,11a,13E)-17,17-propeno-11,16-bis(2-ethylprop-1-en-1-yl)-9-ethylprosta-5,13-diene acid : methyl ester



To a stirred solution of the compound prepared in reference example 18 (less polar: 64 mg) in dichloromethane (1 ml) was added dihydropyran (400 ml) and PPTS (pyridinium p-toluenesulfonate, 4 mg) at room temperature under an atmosphere of argon. The reaction mixture was stirred at room temperature for 8 hours. The reaction mixture was quenched by addition of water and a saturated aqueous solution of sodium hydrogencarbonate, extracted with ethyl acetate (x3). The extract was washed with water (x2) and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (Fuji Silysia BW-300 20 nt, ethyl acetate : hexane = 1 : 7 → 1 : 5) to give the title compound (77.5 mg) as a colorless oil having the following physical data.

TLC: Rf 0.37 (ethyl acetate : hexane = 1 : 4);

NMR (CDCl₃): δ 5.85-5.45 (1H, m), 5.45-5.20 (3H, m), 5.10-4.98 (1H, m), 4.75-4.55 (2H, m), 4.05-3.70 (3H, m), 3.67 (3H, s), 3.65-3.38 (3H, m), 2.60-1.20 (38H, m), 2.04 (3H, s), 1.00-0.85 (3H, m).

Reference example 20

(5Z,9a,11a,13E)-17,17-propeno-11,16-bis(2-ethylprop-1-en-1-yl)-9-hydroxyprosta-5,13-diene acid : methyl ester




To a stirred solution of the compound prepared in reference example 19 (77 mg) in methanol (2 ml) was added potassium carbonate (15 mg) at room temperature under an atmosphere of argon. The reaction mixture was stirred at room temperature for 1 day. The reaction mixture was quenched by addition of water and 1N aqueous solution of hydrochloric acid, extracted with ethyl acetate (x3). The extract was washed with water (x2) and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (Merck 7734, 20 ml, ethyl acetate : hexane = 1 : 4 → 1 : 3) to give the title compound (70 mg) as a colorless oil having the following physical data.

TLC: Rf 0.39 (ethyl acetate : hexane = 1 : 2);

NMR (CDCl₃): δ 5.75 (4H, m), 4.75-4.55 (2H, m), 4.20-3.75 (4H, m), 3.67 (3H, s), 3.62-3.38 (3H, m), 2.60-1.20 (34 H, m), 2.32 (2H, t, J = 7.5 Hz), 0.93 (3H, t, J = 7.5 Hz).

Reference example 21


(5Z,9E,11 α ,13E)-17,17-propiono-11,16-bis(2-(4-ethoxyphenyl)-9-fluoro-prosta-5,13-dienic acid) methyl ester

To a stirred solution of the compound prepared in reference example 20 (70 mg) in dichloromethane (2 ml) was added DAST (20 ml, diethylaminosulfur trifluoride) at -78 °C under an atmosphere of argon. The reaction mixture was stirred for 20 min. The reaction mixture was quenched by addition of water and a saturated aqueous solution of sodium hydrogencarbonate, extracted with ethyl acetate (x2). The extract was washed with water (x2) and a saturated aqueous solution of sodium chloride, successively dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (Fuji Silysia BW-300 20 μ m, ethyl acetate : hexane = 1 : 10) to give the title compound (36 mg) as a colorless oil having the following physical data.

TLC: Rf 0.48 (ethyl acetate : hexane = 1 : 5);

NMR (CDCl₃) : δ 5.90-5.20 (4H, m), 4.75-4.55 (2H, m), 4.40-3.75 (3H, m), 3.67-3.40 (3H, m), 2.60-1.20 (33H, m), 2.32 (2H, t, J = 7.5 Hz), 0.98 (3H, t, J = 6.5 Hz).

Example 14

(5Z,9E,11 α ,13E)-17,17-propiono-11,16-dihydroxy-9-fluoro-prosta-5,13-dienic acid methyl ester

To a stirred mixture of the compound prepared in reference example 21 (66 mg) in THF (1 ml) and water (0.5 ml) was added acetic acid (2 ml) at room temperature. The reaction mixture was stirred at 45 °C. The reaction mixture was quenched by addition of water, extracted with ethyl acetate (x3). The extract was washed with water (x2) and a saturated aqueous solution of sodium chloride, successively dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (Merck 7734, 20 μ m, ethyl acetate : hexane = 1 : 2 \rightarrow 1 : 1) and (Merck Lobar prepacdeg column size A, ethyl acetate : hexane = 2 : 1) to give the present invention compound (12 mg) having the following physical data.

less polar

TLC: Rf 0.54 (ethyl acetate : hexane = 1 : 1);

NMR (CDCl₃) : δ 5.80-5.40 (4H, m), 4.95-4.55 (1H, m), 4.20-4.00 (1H, m), 3.67 (3H, s), 3.54 (1H, dd, J = 10.0, 2.5 Hz), 2.40-1.20 (24H, m), 2.33 (2H, t, J = 7.5 Hz), 0.94 (3H, t, J = 7.0 Hz).

By the same procedure as provided in reference example 19, 20, 21 and example 14, using the compound prepared in reference example 18 (more polar), compound of the present invention having the following physical data was obtained.

more polar

TLC: Rf 0.48 (ethyl acetate : hexane = 1 : 1);

NMR (CDCl₃) : δ 5.80-5.30 (4H, m), 4.95-4.55 (1H, m), 4.20-4.00 (1H, m), 3.67 (3H, s), 3.53 (1H, dd, J = 10.0, 2.0 Hz), 3.00-1.20 (24H, m), 2.32 (2H, t, J = 7.5 Hz), 0.94 (3H, t, J = 6.5 Hz).

Example 15

(5Z,9E,11 α ,13E)-17,17-propiono-11,16-dihydroxy-9-fluoro-prosta-5,13-dienic acid

To a stirred solution of the compound prepared in example 14 (10 mg) in methanol (1 ml) was added 2N aqueous solution of sodium hydroxide (0.3 ml) at room temperature under an atmosphere of argon. The reaction mixture was stirred for 2 hours. The reaction mixture was quenched by addition of water and 1N aqueous solution of hydrochloric acid, extracted with ethyl acetate (x3). The extract was washed with water (x2) and a saturated aqueous solution of sodium chloride, successively dried over anhydrous magnesium sulfate and concentrated to give the present invention compound (10 mg) as a colorless oil having the following physical data.

less polar

TLC: Rf 0.38 (ethyl acetate : hexane = 3 : 1);

NMR (CDCl₃) : δ 5.80-5.30 (4H, m), 5.00-4.60 (1H, m), 4.20-4.00 (1H, m), 3.62 (1H, dd, J = 10.0, 2.0 Hz), 2.34 (2H, t, J = 6.5 Hz), 2.40-1.20 (24H, m), 0.94 (3H, t, J = 6.5 Hz).

By the same procedure as provided in example 15, using the compound prepared in example 14 (more polar), compound of the present invention having the following physical data was obtained.


more polar

TLC: Rf 0.35 (ethyl acetate : hexane = 3 : 1);

NMR (CDCl₃) : δ 5.80-5.30 (4H, m), 5.00-4.80 (1H, m), 4.20-4.00 (1H, m), 3.59 (1H, d, J = 10.5 Hz), 2.35 (2H, t, J = 7.0 Hz), 2.40-1.20 (24H, m), 0.94 (3H, t, J = 6.5 Hz).

Reference example 22

(5Z,9α,11α,13E)-17,17-propano-11,16-bis[(t-butyldimethylsilyloxy)-9-acetyloxy-20-norprosta-5,13-dienic acid methyl ester]




To a stirred solution of (5Z,9α,11α,13E)-17,17-propano-11,16-dihydroxy-9-acetyloxy-20-norprosta-5,13-dienic acid methyl ester (119 mg, more polar; the compound prepared in same method by reference example 18) in dichloromethane (2 ml) was added 2,6-lutidine (0.26 ml) and trifluoromethanesulfonic acid t-butyldimethylsilyl ester (0.26 ml) at 0 °C under an atmosphere of argon. The reaction mixture was stirred at 0 °C for 3 hours. The reaction mixture was quenched by addition of water, extracted with ethyl acetate (x3). The extract was washed with 0.1 N aqueous solution of hydrochloric acid (x2), water and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated to give the title compound (211 mg) as a colorless oil having the following physical data.

TLC: Rf 0.45 (ethyl acetate : hexane = 1 : 8);

NMR (CDCl₃) : δ 5.70-5.45 (1H, m), 5.32 (1H, t, J = 4.5 Hz), 5.25-5.05 (1H, m), 5.05-4.95 (1H, m), 3.90-3.70 (1H, m), 3.6 (3H, s), 3.58 (1H, t, J = 5.0 Hz), 2.50-1.35 (21H, m), 2.29 (2H, t, J = 7.5 Hz), 2.04 (3H, s), 1.00-0.80 (3H, m), 0.91 (3H, s), 0.68 (9H, s), 0.06 (3H, s), 0.05 (3H, s), 0.01 (6H, s).

Reference example 23

(5Z,9α,11α,13E)-17,17-propano-11,16-bis[(t-butyldimethylsilyloxy)-9-hydroxy-20-norprosta-5,13-dienic acid methyl ester]



To a stirred solution of the compound prepared in reference example 22 (211 mg) in methanol (3 ml) was added potassium carbonate (60 mg) under an atmosphere of argon. The reaction mixture was stirred at room temperature for 1 day. The reaction mixture was quenched by addition of water and 1N aqueous solution of hydrochloric acid, extracted with ethyl acetate (x3). The extract was washed with water (x2) and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (Merck 7734, 20 ml, ethyl acetate : hexane = 1 : 8) to give the title compound (161 mg) as a colorless oil having the following physical data.


TLC: Rf 0.35 (ethyl acetate : hexane = 1 : 8);

NMR (CDCl₃) : δ 5.60-5.15 (4H, m), 4.20-4.00 (1H, m), 4.00-3.95 (1H, m), 3.68 (3H, s), 3.57 (1H, t, J = 5.0 Hz),

2.61 (1H, d, J = 9.0 Hz), 2.42-1.35 (20H, m), 2.31 (2H, t, J = 7.5 Hz), 1.00-0.80 (3H, m), 0.90 (9H, s), 0.87 (9H, s), 0.07 (3H, s), 0.05 (3H, s), 0.04 (6H, s).

Reference example 24

(5Z,9α,11α,13E)-17,17-propano-11,16-bis[(t-butyldimethylsilyloxy)-9-oxo-20-norprosta-5,13-dienic acid methyl ester]




To a stirred solution of the compound prepared in reference example 23 (161 mg) in pyridine (1 ml) was added tosyl chloride (102 mg) at 0 °C under an atmosphere of argon. The reaction mixture was stirred at room temperature for 9 hours. The reaction mixture was quenched by addition of water, extracted with ethyl acetate (x3). The extract was washed with a saturated aqueous solution of sodium hydrogencarbonate (x2), water and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated to give the title compound (194 mg) having the following physical data.

TLC: Rf 0.64 (ethyl acetate : hexane = 1 : 18).

Reference example 25


(5Z,9α,11α,13E)-17,17-propano-11,16-bis[(t-butyldimethylsilyloxy)-9-chloro-20-norprosta-5,13-dienic acid methyl ester]



To a stirred solution of tetrabutylammonium chloride (742 mg) was added dropwise a solution of the compound prepared in reference example 24 (194 mg) in toluene (4 ml) under an atmosphere of argon. The reaction mixture was stirred at 40 °C for 12 hours. The reaction solution was changed to white suspension. The reaction mixture was quenched by addition of water, extracted with ethyl acetate (x3). The extract was washed with water (x2), a saturated aqueous solution of sodium hydrogencarbonate (x2) and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated to give the title compound (95 mg) having the following physical data.

TLC: Rf 0.67 (ethyl acetate : hexane = 1 : 8).

Example 16

6 (5Z,9A,11 α ,13E)-17,17-propano-11,16-dihydroxy-9-chloro-20-norprosta-5,13-dienic acid : methyl ester

20

By the same procedure as provided in example 14, using the compound prepared in reference example 25, compound of the present invention having the following physical data was obtained. more polar


28 TLC: Rf 0.49 (ethyl acetate : hexane = 1:1):

NMR (CDCl₃): δ 5.60 (1H, ddd, J=15, 8, 6 Hz), 5.50-5.33 (3H, m), 4.20-3.95 (2H, m), 3.67 (3H, s), 3.53 (1H, dd, J=10.5, 2.5 Hz), 2.32 (2H, t, J=7.0 Hz), 2.40-1.50 (21H, m), 1.45 (1H, sept, J=7.0 Hz), 0.91 (3H, t, J=7.5 Hz).

Example 16(1)-16(8)

By the same procedure as provided in example 16, using the compound prepared in reference example 22, 23, 24, 25 or example 16, compounds of the present invention having the following physical data were obtained.

Example 16(1)

35 (5Z,9A,11 α ,13E)-17,17-propano-11,16-dihydroxy-9-chloroprosta-5,13,19-dienic acid : methyl ester


more polar

63 TLC: Rf 0.49 (ethyl acetate : hexane = 1:1):

NMR (CDCl₃): δ 6.06-5.83 (1H, m), 5.67-5.23 (4H, m), 5.20-5.04 (2H, m), 4.20-3.95 (2H, m), 3.67 (3H, s), 3.53 (1H, dd, J=10.0, 2.5 Hz), 2.60-1.50 (22H, m), 2.32 (2H, t, J=8.0 Hz).

89

Example 16(2)


10 (5Z,9A,11 α ,13E)-17,17-propano-19, 20-methano-11,16-dihydroxy-9-chloroprosta-5,13-dienic acid : methyl ester

more polar

20 TLC: Rf 0.25 (hexane : ethyl acetate = 2:1):

NMR (CDCl₃): δ 5.61 (1H, ddd, J=15.4, 7.8, 5.4 Hz), 5.52-5.35 (3H, m), 4.18-3.94 (2H, m), 3.67 (3H, s), 3.67 (1H, dd, J=10.0, 2.2 Hz), 2.40-1.60 (20H, m), 2.33 (2H, t, J=7.4 Hz), 1.52 (1H, dd, J=14.4, 6.6 Hz), 1.35 (1H, dd, J=14.4, 6.2 Hz), 0.90-0.68 (1H, m), 0.55-0.45 (2H, m), 0.15-0.05 (2H, m).

Example 16(3)

30 (5Z,9A,11 α ,13E)-17,17-propano-11,16-dihydroxy-9-chloro-19-methylprosta-5,19-dienic acid : methyl ester


more polar

45 TLC: Rf 0.32 (hexane : ethyl acetate = 2:1):

NMR (CDCl₃): δ 5.62 (1H, ddd, J=15.4, 7.8, 5.4 Hz), 5.52-5.35 (3H, m), 4.18-3.94 (2H, m), 3.67 (3H, s), 3.61 (1H, dd, J=10.4, 2.2 Hz), 2.40-1.60 (21H, m), 2.33 (2H, t, J=7.4 Hz), 1.56 (1H, dd, J=14.2, 6.9 Hz), 1.33 (1H, dd, J=14.2, 6.8 Hz), 0.918 (3H, d, J=8.6 Hz), 0.915 (3H, d, J=8.6 Hz).

100

Example 16(4)

(5Z,9*E*,11*α*,13*E*)-17,17-propano-11,16-dihydroxy-9-chloropenta-5,13-dienic acid · methyl ester


less polar

20 TLC: Rf 0.28 (hexane : ethyl acetate = 2:1);
NMR (CDCl₃): δ 5.61 (1H, dd, J=15.4, 7.6, 5.6 Hz), 5.55-5.35 (2H, m), 4.20-3.95 (2H, m), 3.68 (3H, s), 3.53 (1H, dd, J=9.8, 2.2 Hz), 2.40-1.20 (24H, m), 2.33 (2H, t, J=7.6 Hz), 0.94 (3H, t, J=6.8 Hz).

more polar

28 TLC: Rf 0.28 (hexane : ethyl acetate = 2:1);
NMR (CDCl₃): δ 5.58 (1H, dd, J=15.0, 8.2, 5.6 Hz), 5.50-5.32 (2H, m), 4.18-3.95 (2H, m), 3.67 (3H, s), 3.53 (1H, dd, J=10.4, 2.2 Hz), 2.78 (1H, br), 2.40-1.20 (23H, m), 2.33 (2H, t, J=7.3 Hz), 0.94 (3H, t, J=6.8 Hz).


Example 16(5)

(5Z,9*E*,11*α*,13*E*)-17,17-propano-11,16-dihydroxy-9-chloro-19,20-dinorprosta-5,13-dienic acid · methyl ester

more polar

50 TLC: Rf 0.30 (hexane : ethyl acetate = 1:1);
NMR (CDCl₃): δ 5.59 (1H, dd, J=15.3, 8.6 Hz), 5.47-5.30 (2H, m), 4.18-3.95 (2H, m), 3.67 (3H, s), 3.53 (1H, dd, J=10.2 Hz), 2.40-1.55 (22H, m), 1.14 (3H, s).


Example 16(6)

(5Z,9*E*,11*α*,13*E*)-17,17-propano-11,16-dihydroxy-9-chloro-18,19,20-trinorprosta-5,13-dienic acid · methyl ester

more polar

20 TLC: Rf 0.28 (hexane : ethyl acetate = 1:1);
NMR (CDCl₃): δ 5.60 (1H, dd, J=15.5, 8.6 Hz), 5.49-5.31 (2H, m), 4.19-3.95 (2H, m), 3.67 (3H, s), 3.62-3.48 (1H, m), 2.60-1.60 (23H, m).

Example 17

(5Z,9*E*,11*α*,13*E*)-17,17-propano-11,16-dihydroxy-9-chloro-20-norprosta-5,13-dienic acid

45 By the same procedure as provided in example 15, using the compound prepared in example 16, compound of the present invention having the following physical data was obtained.

more polar


50 TLC: Rf 0.44 (ethyl acetate : hexane : acetic acid = 6:3:0.1);
NMR (CDCl₃): δ 5.60-5.35 (4H, m), 4.20-4.00 (2H, m), 3.59 (1H, dd, J=10.5, 2.5 Hz), 2.38 (2H, t, J=7.0 Hz), 2.40-1.80 (19H, m), 1.45 (1H, sept, J=7.5 Hz), 0.82 (3H, t, J=7.5 Hz).

Example 17(1)-17(6)

55 By the same procedure as provided in example 17, using the compound prepared in example 16(1)-16(6), compounds of the present invention having the following physical data were obtained.

Example 17(1)

(5Z,9E,11c,13E)-17,17-propano-11,16-dihydroxy-9-chloropenta-5,13,19-trienic acid




20 more polar

TLC: Rf 0.44 (ethyl acetate : hexane : acetic acid = 6:3:0.1);
 NMR (CDCl₃): δ 6.95 (1H, dd, J=17.0, 10.0, 2.0 Hz), 5.70-5.32 (4H, m), 5.20-5.00 (2H, m), 4.20-4.00 (2H, m), 3.59 (1H, dd, J=10.0, 2.0 Hz), 2.36 (2H, t, J=7.0 Hz), 2.40-1.60 (20H, m).

Example 17(2)

(5Z,9E,11c,13E)-17,17-propano-19,20-methano-11,16-dihydroxy-9-chloropenta-5,13-dienic acid




40 more polar

TLC: Rf 0.31 (hexane : ethyl acetate : acetic acid = 3:2:0.05);
 NMR (CDCl₃): δ 5.60 (1H, dd, J=15.4, 7.6, 5.4 Hz), 5.55-5.35 (3H, m), 4.20-3.98 (2H, m), 4.20-3.00 (3H, br), 3.71 (1H, dd, J=10.4, 2.2 Hz), 2.40-1.60 (18H, m), 2.36 (2H, t, J=6.9 Hz), 1.51 (1H, dd, J=14.2, 6.8 Hz), 1.37 (1H, dd, J=14.2, 6.2 Hz), 0.90-0.65 (1H, m), 0.57-0.45 (2H, m), 0.15-0.05 (2H, m).

Example 17(3)

(5Z,9E,11c,13E)-17,17-propano-11,16-dihydroxy-9-chloro-19-methylpenta-5,13-dienic acid




20 more polar

TLC: Rf 0.34 (hexane : ethyl acetate : acetic acid = 3:2:0.05);
 NMR (CDCl₃): δ 5.60 (1H, dd, J=15.4, 8.2, 5.6 Hz), 5.55-5.35 (3H, m), 4.20-3.98 (2H, m), 4.20-3.00 (3H, br), 3.65 (1H, dd, J=10.2, 2.2 Hz), 2.40-1.65 (19H, m), 2.36 (2H, t, J=7.1 Hz), 1.55 (1H, dd, J=14.2, 6.6 Hz), 1.33 (1H, dd, J=14.2, 6.2 Hz), 0.92 (3H, d, J=6.6 Hz), 0.91 (3H, d, J=6.6 Hz).

Example 17(4)

(5Z,9E,11c,13E)-17,17-propano-11,16-dihydroxy-9-chloropenta-5,13-dienic acid



40 less polar


TLC: Rf 0.33 (hexane : ethyl acetate : acetic acid = 3:2:0.05);
 NMR (CDCl₃): δ 5.60 (1H, dd, J=15.4, 7.8, 5.6 Hz), 5.55-5.37 (3H, m), 4.20-4.00 (2H, m), 4.20-3.00 (3H, br), 3.60 (1H, dd, J=10.0, 2.2 Hz), 2.40-1.20 (22H, m), 2.35 (2H, t, J=6.9 Hz), 0.84 (3H, t, J=6.8 Hz).

60 more polar

TLC: Rf 0.31 (hexane : ethyl acetate : acetic acid = 3:2:0.05);
 NMR (CDCl₃): δ 5.53 (1H, dd, J=15.4, 7.6, 5.4 Hz), 5.55-5.35 (3H, m), 4.20-4.00 (2H, m), 4.00-3.00 (3H, br), 3.57 (1H, dd, J=10.2, 2.2 Hz), 2.40-1.20 (22H, m), 2.38 (2H, t, J=6.9 Hz), 0.84 (3H, t, J=6.8 Hz).

Example 17(5)

(5Z,9R,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloro-18,20-dinorprosta-5,13-dienolic acid




more polar

TLC: Rf 0.32 (hexane : ethyl acetate : acetic acid = 2 : 3 : 0.04);

NMR (CDCl₃) : δ 5.60 (1H, ddd, J = 15, 8, 6 Hz), 5.55-5.35 (9H, m), 4.20-4.00 (2H, m), 4.00-3.00 (3H, br), 3.57 (1H, dd, J = 10, 2 Hz), 2.40-1.50 (20H, m), 1.14 (3H, s).

Example 17(6)

(5Z,9R,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloro-18,19,20-trinorprosta-5,13-dienolic acid




more polar

TLC: Rf 0.25 (hexane : ethyl acetate : acetic acid = 2 : 3 : 0.04);

NMR (CDCl₃) : δ 5.59 (1H, ddd, J = 15, 8, 6 Hz), 5.54-5.33 (3H, m), 4.20-3.98 (2H, m), 4.00-3.00 (3H, br), 3.62-3.50 (1H, m), 2.60-1.55 (21H, m).

Reference example 26

(5Z,9R,11a,13E)-17,17-propano-11,16-bis[(t-butylidimethylsilyl)oxy]-9-formyloxy-prosta-5,13-dienolic acid : methyl ester




To a stirred solution of the compound prepared in reference example 16 (330 mg) in THF (1.5 ml) was added formic acid (25 ml) and triphenylphosphine (160 mg) under an atmosphere of argon. To the mixture was added dropwise DEAD (0.1 ml; diethylazodicarboxylate) at 0 °C. The reaction mixture was stirred for 30 min. The reaction mixture was quenched by addition of water, extracted with ethyl acetate (x3). The extract was washed with water (x2) and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (Merck 7734, 15 ml, ethyl acetate : hexane = 0 : 1 \rightarrow 1 : 20) to give the title compound (20 mg) as a yellow oil having the following physical data.

TLC: Rf 0.56 (ethyl acetate : hexane = 1 : 9);

NMR (CDCl₃) : δ 7.99 (1H, s), 5.65-5.17 (4H, m), 5.04-4.90 (1H, m), 3.94 (1H, q, J = 7.5 Hz), 3.68 (9H, s), 3.56 (1H, t, J = 5.5 Hz), 2.30 (2H, t, J = 7.5 Hz), 2.40-1.20 (23H, m), 0.91 and 0.90 (9H, each-s), 0.88 (9H, s), 1.00-0.80 (3H, m), 0.06 (3H, s), 0.05 (3H, s), 0.01 (6H, s).

Reference example 27

(5Z,9R,11a,13E)-17,17-propano-11,16-bis[(t-butylidimethylsilyl)oxy]-9-hydroxyprosta-5,13-dienolic acid : methyl ester




To a stirred solution of the compound prepared in reference example 26 (20 mg) in methanol (1 ml) was added ammonia in water solution (0.1 ml) at room temperature under an atmosphere of argon. The reaction mixture was stirred for 30 min. The reaction mixture was quenched by addition of a saturated aqueous solution of ammonium chloride, extracted with ethyl acetate. The extract was washed with water (x2) and a saturated aqueous solution of sodium chloride, successively, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (Merck 7734, 15 ml, ethyl acetate : hexane = 1 : 8 \rightarrow 1 : 4) to give the title compound (15 mg) as a colorless oil having the following physical data.

TLC: Rf 0.18 (ethyl acetate : hexane = 1 : 8);

NMR (CDCl_3): δ 5.62-5.18 (4H, m), 4.10-3.90 (2H, m), 3.67 (3H, s), 3.55 (1H, t, J = 5.5 Hz), 2.32 (2H, t, J = 8.0 Hz), 2.40-1.20 (23H, m), 1.00-0.80 (8H, m), 0.90 and 0.89 (8H, each s), 0.86 (8H, s), 0.06 (3H, s), 0.04 (3H, s), 0.01 (6H, s).

Reference example 28

(5Z,9 α ,11 α ,13E)-17,17-propano-11,16-bis((butyldimethylsilyloxy)-9-oxo-9-oxo-prosta-5,13-diene acid : methyl ester




By the same procedure as provided in reference example 24, using the compound prepared in reference example 27, title compound having the following physical data was obtained.

TLC: Rf 0.47 (ethyl acetate : hexane = 6 : 1).

Reference example 29

(5Z,9 α ,11 α ,13E)-17,17-propano-11,16-bis((butyldimethylsilyloxy)-9-oxo-prosta-5,13-diene acid : methyl ester




By the same procedure as provided in reference example 25, using the compound prepared in reference example 28, title compound having the following physical data was obtained.

TLC: Rf 0.45 (ethyl acetate : hexane = 1 : 20);

NMR (CDCl_3): δ 5.72-5.10 (4H, m), 4.35-4.25 (1H, m), 3.95-3.75 (1H, m), 3.66 (3H, s), 3.57 (1H, t, J = 5.5 Hz), 2.54 (2H, ddd, J = 15.0, 9.0, 6.0 Hz), 2.50-1.20 (21H, m), 2.31 (2H, t, J = 8.0 Hz), 1.00-0.80 (3H, m), 0.91 and 0.90 (8H, each s), 0.86 (8H, s), 0.10-0.00 (6H, m), 0.07 (6H, s).

Example 18

(5Z,9 α ,11 α ,13E)-17,17-propano-11,16-dihydroxy-9-chloro-prosta-5,13-diene acid : methyl ester



By the same procedure as provided in example 1, using the compound prepared in reference example 25, compound of the present invention having the following physical data was obtained.

less polar

TLC: Rf 0.56 (ethyl acetate : hexane = 1 : 1);

NMR (CDCl_3): δ 5.66 (1H, ddd, J = 15.5, 8.0, 6.0 Hz), 5.50-5.30 (3H, m), 4.38 (1H, t, J = 5.0 Hz), 4.10-3.90 (1H, m), 3.67 (3H, s), 3.56 (1H, dd, J = 10.0, 2.0 Hz), 2.70-1.20 (22H, m), 2.33 (2H, t, J = 8.0 Hz), 0.94 (3H, t, J = 7.0 Hz).


more polar

TLC: Rf 0.47 (ethyl acetate : hexane = 1 : 1);

NMR (CDCl_3): δ 5.66 (1H, ddd, J = 15.5, 8.0, 6.5 Hz), 5.50-5.30 (3H, m), 4.38 (1H, t, J = 5.0 Hz), 3.93 (1H, ddd, J = 9.0, 6.0, 2.5 Hz), 3.67 (3H, s), 3.56 (1H, dd, J = 10.0, 2.0 Hz), 2.70-1.20 (22H, m), 2.32 (2H, t, J = 7.5 Hz), 0.94 (3H, t, J = 7.0 Hz).

Example 19

(5Z,9 α ,11 α ,13E)-17,17-propano-11,16-dihydroxy-9-chloro-prosta-5,13-diene acid



By the same procedure as provided in example 15, using the compound prepared in example 18, compound of the present invention having the following physical data was obtained.

less polar


TLC: Rf 0.47 (ethyl acetate : hexane = 2:1);
NMR (CDCl₃): δ 5.75-5.30 (4H, m), 4.44 (1H, t, J=4.5 Hz), 3.97 (1H, ddd, J=9.0, 6.0, 3.5 Hz), 3.68 (1H, d, J=10.0, 2.0 Hz), 2.70-1.20 (22H, m), 2.34 (2H, t, J=6.5 Hz), 0.94 (3H, t, J=6.5 Hz).

more polar

TLC: Rf 0.47 (ethyl acetate : hexane = 2:1);
NMR (CDCl₃): δ 5.67 (1H, dt, J=15.5, 6.5 Hz), 5.50-5.30 (3H, m), 4.42 (1H, t, J=5.0 Hz), 4.03 (1H, ddd, J=9.0, 6.0, 3.0 Hz), 3.68 (1H, d, J=9.5, 2.5 Hz), 2.70-1.20 (22H, m), 2.34 (2H, t, J=7.0 Hz), 0.94 (3H, t, J=6.5 Hz).

Reference example 30

(5Z,8Z,11α,13E)-17,17-propano-11,16-bis-(butyldimethylsilyloxy)-9-acetyloxy-prosta-5,8,13-trienic acid methyl ester




To a solution of (1E,4R)-1-iodo-4-(butyldimethylsilyloxy)-5,5-propano-2-ene (407 mg) in anhydrous ether (3 ml) was added dropwise t-butyllithium (1.21 ml, 1.7 M pentane solution) at -78 °C. After the mixture was stirred for 60 min, to the mixture was added dropwise lithium 2-thienylacrylate (4.8 ml, 0.25 M tetrahydrofuran solution) at same temperature. After the mixture was stirred for 20 min, to the mixture was added dropwise a solution of (5Z)-7-(3R)-3-(butyldimethylsilyloxy)-5-oxocyclopent-1-ene (234 mg) in ether (4 ml). After the mixture was warmed up to -20 °C for 45 min, to the mixture was added acetic anhydride (1.88 ml). The reaction mixture was stirred at 0 °C for 30 min. The reaction mixture was quenched by addition of a saturated aqueous solution of ammonium chloride, extracted with hexane. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (Wako gel C-200, 40 ml, hexane : ethyl acetate = 1 : 0 → 50 : 1 → 20 : 1) to give the title compound (324 mg) having the following physical data.

TLC: Rf 0.50 (hexane : ethyl acetate = 8 : 1);
NMR (CDCl₃): δ 5.70-5.45 (1H, m), 5.45-5.15 (3H, m), 4.14-4.02 (1H, m), 3.68 (3H, s), 3.55 (1H, t, J=5.1 Hz), 3.05-2.92 (1H, m), 2.93-2.68 (2H, m), 2.60-2.30 (2H, m), 2.30 (2H, t, J=7.6 Hz), 2.20-1.20 (18H, m), 2.13 (3H, s), 1.00-0.90 (21H, m), 0.10-0.00 (12H, m).

Example 20

(5Z,8Z,11α,13E)-17,17-propano-11,16-dihydroxy-9-acetyloxy-prosta-5,8,13-trienic acid methyl ester



By the same procedure as provided in example 1, using the compound prepared in reference example 30, compounds of the present invention having the following physical data were obtained.

less polar


TLC: Rf 0.44 (hexane : ethyl acetate = 1:1);
NMR (CDCl₃): δ 5.63 (1H, ddd, J=15.4, 7.4, 6.0 Hz), 5.50-5.25 (3H, m), 4.18-4.02 (1H, m), 3.67 (3H, s), 3.52 (1H, d, J=9.6, 2.2 Hz), 3.10-3.00 (1H, m), 3.00-2.72 (2H, m), 2.66-2.40 (2H, m), 2.40-1.20 (18H, m), 2.32 (2H, t, J=7.2 Hz), 2.16 (3H, s), 0.93 (3H, t, J=6.8 Hz).

more polar

TLC: Rf 0.38 (hexane : ethyl acetate = 1:1);
NMR (CDCl₃): δ 5.62 (1H, ddd, J=15.4, 7.6, 6.2 Hz), 5.50-5.25 (3H, m), 4.18-4.02 (1H, m), 3.67 (3H, s), 3.52 (1H, d, J=9.6, 2.2 Hz), 3.10-3.00 (1H, m), 2.88-2.72 (2H, m), 2.66-2.40 (2H, m), 2.40-1.20 (18H, m), 2.31 (2H, t, J=7.4 Hz), 2.16 (3H, s), 0.93 (3H, t, J=6.9 Hz).

Reference example 31

(5Z,11α,13E)-17,17-propano-11,16-bis-(butyldimethylsilyloxy)-1,9-dihydroxyprosta-5,13-diene




To a solution of the compound prepared in reference example 3 (174 mg) in THF (3 ml) was added dropwise DIBAL (1.16 ml, 0.95 M hexane solution) at -78 °C. The reaction mixture was stirred at 0 °C for 30 min, and stirred at room temperature for 30 min. To the reaction mixture was added dropwise a saturated aqueous solution of sodium sulfate (0.3 ml), diluted with ether. The mixture was stirred at room temperature for 30 min, the reaction mixture was dried over anhydrous magnesium sulfate and concentrated to give the title compound (160 mg) having the following physical data.

TLC: Rf 0.40 (9:1 OH form) and 0.24 (9:1 OH form) (hexane : ethyl acetate = 3 : 1).

Reference example 32

(5Z,11a,13E)-17,17-propano-1,11,16-tris(4-butylidimethylsilyloxy)-9-hydroxyprosta-5,13-diene




To a solution of the compound prepared in reference example 31 (150 mg) and pyridine (44 ml) in dichloromethane (3 ml) was added TBSO (45 mg; 1-butylidimethylsilyl chloride) under cooling with ice. The reaction mixture was stirred at room temperature for overnight. To the reaction mixture was added pyridine (50 ml) and TBSO (50 mg). The reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was quenched by addition of a saturated aqueous solution of sodium hydrogencarbonate, extracted with hexane. The extract was dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (Merck 7734, 20 g; hexane : ethyl acetate = 1 : 0 → 20 : 1 → 10 : 1) to give the title compound (total 142 mg) having the following physical data.

TLC: Rf 0.62 (9:1 OH form) and 0.46 (9:1 OH form) (hexane : ethyl acetate = 9 : 1);
NMR (CDCl₃): δ 5.90-5.15 (4H, m), 4.10-3.90 (2H, m), 3.65-3.45 (3H, m), 2.40-1.20 (24H, m), 1.00-0.90 (30H, m), 0.10-0.00 (18H, m).

Reference example 33

(5Z,11a,13E)-17,17-propano-1,11,16-tris(4-butylidimethylsilyloxy)-9-oxoprosta-5,13-diene




To a solution of oxaly chloride (33 ml) in dichloromethane (0.5 ml) was added dropwise dimethylsulfoxide (55 ml) at -78 °C. After the mixture was stirred for 10 min, to the mixture was added dropwise a solution of the compound prepared in reference example 32 (140 mg) in dichloromethane (3 ml). After the mixture was warmed up to -40 °C for 1 hour, to the mixture added dropwise triethylamine (0.22 ml). The reaction mixture was warmed up to -10 °C for 1 hour. The reaction mixture was quenched by addition of water and 2N aqueous solution of hydrochloric acid (0.7 ml), extracted with hexane. The extract was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography on silica gel (Wako

gel C-200, 15 g, hexane : ethyl acetate = 1 : 0 → 30 : 1) to give the title compound (112 mg) having the following physical data.

TLC: Rf 0.80 (hexane : ethyl acetate = 9 : 1);
NMR (CDCl₃): δ 5.70-5.20 (4H, m), 4.05-3.90 (1H, m), 3.55 (2H, t, J=6.3 Hz), 3.55-3.50 (1H, m), 2.65-1.20 (24H, m), 1.00-0.90 (30H, m), 0.10-0.00 (18H, m).

Example 21

(5Z,11a,13E)-17,17-propano-1,11,16-dihydroxy-9-oxoprosta-5,13-diene-1-ol



By the same procedure as provided in example 1, using the compound prepared in reference example 33, compounds of the present invention having the following physical data were obtained.

less polar

TLC: Rf 0.40 (hexane : ethyl acetate : methanol = 1 : 3 : 0.04);
NMR (CDCl₃): δ 5.78 (1H, dt, J=15.2, 7.0 Hz), 5.45 (1H, dd, J=15.2, 7.8 Hz), 5.50-5.20 (2H, m), 4.12-3.88 (1H, m), 3.70-3.59 (2H, m), 3.50 (1H, dd, J=10.4, 2.6 Hz), 2.74 (1H, ddd, J=18.2, 7.2, 1.0 Hz), 2.55-1.20 (26H, m), 0.94 (3H, t, J=7.4 Hz).

more polar

TLC: Rf 0.37 (hexane : ethyl acetate : methanol = 1 : 3 : 0.04);
NMR (CDCl₃): δ 5.71 (1H, ddd, J=15.4, 8.2, 5.3 Hz), 5.50-5.20 (3H, m), 4.10-3.95 (1H, m), 3.64 (2H, t, J=6.4 Hz), 3.58 (1H, dd, J=10.2, 2.4 Hz), 2.73 (1H, ddd, J=18.0, 7.6, 1.0 Hz), 2.50-1.20 (26H, m), 0.94 (3H, t, J=6.8 Hz).

Formulation example

Formulation example 1

The following compounds were admixed in conventional method, dried, added microcrystalline cellulose, mixed until homogeneous and punched out to obtain 100 tablets each containing 30 µg of active ingredient.


• The solution of (5Z,11a,13E)-11,16-dihydroxy-9-oxo-17,17-propanoprost-5,13-dieneic acid (3 mg) in ethanol	10 mL
• Magnesium stearate	100 mg
• silicon dioxide	20 mg

(continued)

• basic	10 mg
• Carboxymethylcellulose calcium	200 mg
• Microcrystalline cellulose	5.0 g

Claims

1. An α -cycloalkyl-prostaglandin E₂ derivative of formula (I)



wherein R is carboxy or hydroxymethyl;

R¹ is oxo, methylene or halogen atom;

R² is hydrogen atom, hydroxy or C1-4 alkoxy;

R³ is hydrogen atom, C1-8 alkyl, C2-8 allyl, C2-8 alkenyl or C2-8 alkynyl substituted by 1-3 substituents selected from (1)-(5);

(1) halogen atom,

(2) C1-4 alkoxy,

(3) C3-7 cycloalkyl,

(4) phenyl, and

(5) phenyl substituted by 1-3 substituents selected from halogen atom, C1-4 alkyl, C1-4 alkoxy, nitro and trifluoromethyl;

n is 0-4;


is single bond or double bond;

is double bond or triple bond; and

is a single bond, double bond or triple bond;


and wherein the double bond at the 13-14 position, when present, is in the E, Z or EZ mixture form; with the proviso that when the 5-6 position is a triple bond, the 13-14 position is not a triple bond; or a non-toxic salt thereof, prodrug thereof or cyclooxin derivative thereof.

2. A compound according to claim 1, which is a prodrug of formula (IA)




wherein R¹⁰ is C1-6 alkyl and the other symbols are as defined in claim 1.

3. A compound according to claim 1, which is a prodrug of formula (IB)



wherein R¹² and R¹³ each, independently, is hydrogen atom or C1-6 alkyl and the other symbols are as defined in claim 1.

4. A compound according to claim 1, which is a prodrug of formula (IC)



wherein R¹⁰ is C1-6 alkyl, R¹¹ is C1-4 alkyl, C1-4 alkoxy, phenyl, phenyl-C1-4 alkyl, R¹⁴-OOC-C1-4 alkyl or R¹⁴-OOC-C2-4 alkenyl (in which R¹⁴ is hydrogen atom or C1-4 alkyl) and the other symbols are as defined in claim 1.

5. A compound according to claim 1, wherein R is carboxy.

6. A compound according to claim 1, wherein R is hydroxymethyl.

7. A compound according to claim 2, which is

- (1) (5Z,11a,13E)-11,16-dihydroxy-9-oxo-17,17-propanoproposta-5,13-dienic acid · methyl-ester,
- (2) (5Z,11a,13E)-11,16-dihydroxy-9-oxo-17,17-propanoproposta-5-ene-19-ynoic acid · methyl-ester,
- (3) (11a,13E)-11,16-dihydroxy-9-oxo-17,17-propanoproposta-13-ene-19-ynoic acid · methyl-ester,
- (4) (5Z,11a,13E)-11,16-dihydroxy-9-oxo-17,17-propanoproposta-5-ene-19-ynoic acid · methyl-ester,
- (5) (5Z,11a,13E)-11,16-dihydroxy-20-methyl-9-oxo-17,17-propanoproposta-5,13-dienic acid · methyl-ester,
- (6) (5Z,11a,13E)-11,16-dihydroxy-20-ethyl-9-oxo-17,17-propanoproposta-5,13-dienic acid · methyl-ester,
- (7) (5Z,11a,13E)-11,16-dihydroxy-20-methyl-9-oxo-17,17-propanoproposta-5,13-dienic acid · methyl-ester,
- (8) (5Z,11a,13E)-11,16-dihydroxy-20-ethyl-9-oxo-17,17-propanoproposta-5,13-dienic acid · methyl-ester,
- (9) (5Z,11a,13E)-11,16-dihydroxy-9-oxo-17,17-propanoproposta-5,13,19-trienic acid · methyl-ester,
- (10) (5Z,11a,13E)-11,16-dihydroxy-20-methyl-9-oxo-17,17-propanoproposta-5,13,19-trienic acid · methyl-ester,
- (11) (5Z,11a,13E)-11,16-dihydroxy-9-oxo-17,17-pentanoproposta-5,13-dienic acid · methyl-ester,
- (12) (5Z,11a,13E)-11,16-dihydroxy-9-oxo-17,17-pentanoproposta-5,13-dienic acid · methyl-ester,
- (13) (5Z,11a,13E)-18-cyclohexyl-11,16-dihydroxy-9-oxo-17,17-propano-19,20-dinorproposta-5,13-dienic acid · methyl-ester,
- (14) (5Z,11a,13E)-11,16-dihydroxy-9-oxo-17,17-propano-20-norproposta-5,13-dienic acid · methyl-ester,
- (15) (5Z,11a,13E)-17,17-propano-18,20-methano-11,16-dihydroxy-9-oxoproposta-5,13-dienic acid · methyl-ester,
- (16) (5Z,11a,13E)-17,17-propano-20,20-methylene-11,16-dihydroxy-9-oxoproposta-5,13-dienic acid · methyl-ester,
- (17) (5Z,11a,13E)-17,17-propano-20-methoxy-11,16-dihydroxy-9-oxoproposta-5,13-dienic acid · methyl-ester,
- (18) (5Z,11a,13E)-17,17-propano-20-fluoro-11,16-dihydroxy-9-oxoproposta-5,13-dienic acid · methyl-ester,
- (19) (5Z,11a,13E)-17,17-propano-19-methyl-11,16-dihydroxy-9-oxoproposta-5,13-dienic acid · methyl-ester,
- (20) (5Z,11a,13E)-17,17-propano-11,16-dihydroxy-9-oxo-20-norproposta-5,13,19-trienic acid · methyl-ester,
- (21) (5Z,11a,13E)-17,17-propano-15-hydroxy-16-hydroxy-9-oxoproposta-5,13-dienic acid · methyl-ester,
- (22) (5Z,11a,13E)-17,17-propano-11-methoxy-16-hydroxy-9-oxoproposta-5,13-dienic acid · methyl-ester,
- (23) (5Z,11a,13E)-17,17-propano-11-methoxy-16-hydroxy-9-oxo-18-methylproposta-5,13-dienic acid · methyl-ester,
- (24) (5Z,11a,13E)-17,17-propano-11-methoxy-16-hydroxy-9-oxo-19,20-methanoproposta-5,13-dienic acid · methyl-ester,
- (25) (5Z,11a,13E)-17,17-propano-11-methoxy-16-hydroxy-9-oxo-20-norproposta-5,13-dienic acid · methyl-ester,
- (26) (5Z,11a,13E)-17,17-propano-11-methoxy-16-hydroxy-9-oxoproposta-5,13,19-trienic acid · methyl-ester,
- (27) (5Z,11a,13E)-17,17-propano-11,16-dihydroxy-9,9-methyleneproposta-5,13-dienic acid · methyl-ester,
- (28) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-fluoroproposta-5,13-dienic acid · methyl-ester,
- (29) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloroproposta-5,13-dienic acid · methyl-ester,
- (30) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloro-20-norproposta-5,13,19-trienic acid · methyl-ester,
- (31) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloroproposta-5,13,19-trienic acid · methyl-ester,
- (32) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloro-19-methylproposta-5,13-dienic acid · methyl-ester,
- (33) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloroproposta-5,13-dienic acid · methyl-ester,
- (34) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloroproposta-5,13-dienic acid · methyl-ester,
- (35) (5Z,11a,13E)-17,17-propano-11,16-dihydroxy-9-oxo-19,20-dinorproposta-5,13-dienic acid · methyl-ester,
- (36) (5Z,11a,13E)-17,17-propano-11,16-dihydroxy-9-oxo-18,19,20-trinorproposta-5,13-dienic acid · methyl-ester,
- (37) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloro-19,20-dinorproposta-5,13-dienic acid · methyl-ester, or
- (38) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloro-18,19,20-trinorproposta-5,13-dienic acid · methyl-ester,
- (39) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloro-18,19,20-trinorproposta-5,13-dienic acid · methyl-ester,

8. A compound according to claim 3, which is

(1) (5Z,11a,13E)-17,17-propano-11,16-dihydroxy-9-oxoproposta-5,13-dienic acid amide, in the form of the more or less polar stereoisomer on the 16-position or a mixture thereof.

9. A compound according to claim 4, which is

(1) (5Z,8Z,11a,13E)-17,17-propano-11,16-dihydroxy-9-acetyloxoproposta-5,8,13-trienic acid · methyl-ester, in the form of the more or less polar stereoisomer on the 16-position or a mixture thereof.


10. A compound according to claim 5, which is

- (1) (5Z,11a,13E)-11,16-dihydroxy-9-oxo-17,17-propanoproposta-5,13-dienic acid,
- (2) (5Z,11a,13E)-11,16-dihydroxy-20-methyl-9-oxo-17,17-propanoproposta-5,13-dienic acid,
- (3) (5Z,11a,13E)-11,16-dihydroxy-20-ethyl-9-oxo-17,17-propanoproposta-5,13-dienic acid,
- (4) (5Z,11a,13E)-20-chloro-11,16-dihydroxy-9-oxo-17,17-propanoproposta-5,13-dienic acid,
- (5) (5Z,11a,13E)-11,16-dihydroxy-9-oxo-18-phenyl-17,17-propano-19,20-dinorproposta-5,13-dienic acid,
- (6) (5Z,11a,13E)-11,16-dihydroxy-20-methyl-9-oxo-17,17-propanoproposta-5,13,19-trienic acid,
- (7) (5Z,11a,13E)-11,16-dihydroxy-20-methyl-9-oxo-17,17-propanoproposta-5,13-dienic acid,
- (8) (5Z,11a,13E)-17,17-bulano-11,16-dihydroxy-9-oxoproposta-5,13-dienic acid,
- (9) (5Z,11a,13E)-11,16-dihydroxy-9-oxo-17,17-pentanoproposta-5,13-dienic acid,
- (10) (5Z,11a,13E)-18-cyclohexyl-11,16-dihydroxy-9-oxo-17,17-propano-19,20-dinorproposta-5,13-dienic acid,
- (11) (5Z,11a,13E)-11,16-dihydroxy-9-oxo-17,17-propano-20-norproposta-5,13-dienic acid,
- (12) (5Z,11a,13E)-11,16-dihydroxy-9-oxo-17,17-propanoproposta-5-ene-13-ynoic acid,
- (13) (5Z,11a,13E)-11,16-dihydroxy-9-oxo-17,17-propanoproposta-5-ene-13-ynoic acid,
- (14) (11a,13E)-11,16-dihydroxy-9-oxo-17,17-propanoproposta-13-ene-5-ynoic acid,
- (15) (5Z,11a,13E)-17,17-propano-19,20-methanol-11,16-dihydroxy-9-oxoproposta-5,13-dienic acid,
- (16) (5Z,11a,13E)-17,17-propano-20-methylene-11,16-dihydroxy-9-oxoproposta-5,13-dienic acid,
- (17) (5Z,11a,13E)-17,17-propano-20-methoxy-11,16-dihydroxy-9-oxoproposta-5,13-dienic acid,
- (18) (5Z,11a,13E)-17,17-propano-20-fluoro-11,16-dihydroxy-9-oxoproposta-5,13-dienic acid,
- (19) (5Z,11a,13E)-17,17-propano-19-methyl-11,16-dihydroxy-9-oxoproposta-5,13-dienic acid,
- (20) (5Z,11a,13E)-17,17-propano-11,16-dihydroxy-9-oxo-20-norproposta-5,13,19-trienic acid,
- (21) (5Z,11a,13E)-17,17-propano-11,16-dihydroxy-9-oxoproposta-5,13-dienic acid,
- (22) (5Z,13E)-17,17-propano-16-hydroxy-9-oxoproposta-5,13-dienic acid,
- (23) (5Z,11a,13E)-17,17-propano-11-methoxy-16-hydroxy-9-oxoproposta-5,13-dienic acid,
- (24) (5Z,11a,13E)-17,17-propano-11-methoxy-16-hydroxy-9-oxo-19,20-methanoproposta-5,13-dienic acid,
- (25) (5Z,11a,13E)-17,17-propano-11-methoxy-16-hydroxy-9-oxo-20-norproposta-5,13-dienic acid,
- (26) (5Z,11a,13E)-17,17-propano-11-methoxy-16-hydroxy-9-oxoproposta-5,13,19-trienic acid,
- (27) (5Z,11a,13E)-17,17-propano-11,16-dihydroxy-9,9-methyleneproposta-5,13,19-trienic acid,
- (28) (5Z,11a,13E)-17,17-propano-11,16-dihydroxy-9-fluoroproposta-5,13-dienic acid,
- (29) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloro-20-norproposta-5,13-dienic acid,
- (30) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloroproposta-5,13,19-trienic acid,
- (31) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloroproposta-5,13-dienic acid,
- (32) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloro-19-methylproposta-5,13-dienic acid,
- (33) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloro-19-methylproposta-5,13-dienic acid,
- (34) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloroproposta-5,13-dienic acid,
- (35) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloro-19,20-dinorproposta-5,13-dienic acid,
- (36) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-oxo-18,19,20-trinorproposta-5,13-dienic acid,
- (37) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloro-18,19,20-trinorproposta-5,13-dienic acid, or
- (38) (5Z,9a,11a,13E)-17,17-propano-11,16-dihydroxy-9-chloro-18,19,20-trinorproposta-5,13-dienic acid, in the form of the more or less polar stereoisomer on the 16-position or a mixture thereof.

11. A compound according to claim 6, which is


(1) (5Z,11a,13E)-17,17-propano-11,16-dihydroxy-9-oxoproposta-5,13-diene-1-ol, in the form of the more or less polar stereoisomer on the 16-position or a mixture thereof.

12. A process for the preparation of a compound of formula (I) as defined in claim 1, which is of formula (I-1)




wherein all the symbols are as defined in claim 1,
which process comprises hydrolysis using an enzyme or hydrolysis under alkaline conditions of a compound of formula (IA) as defined in claim 2.

13. A process for the preparation of a compound of formula (I) as defined in claim 1, which is of formula (I-2A)




wherein all the symbols are as defined in claim 1,
which process comprises elimination under acidic conditions of the protecting group(s) of a compound of formula (IIA)




wherein R²⁰ is hydrogen atom, hydroxy protecting group which may be eliminated under acidic conditions or C1-4 alkoxy, R⁴⁰ is hydroxy protecting group which may be eliminated under acidic conditions, and the other symbols are as defined in claim 1.

14. A process for the preparation of a compound of formula (I) as defined in claim 1, which is of formula (I-2B)




wherein all the symbols are as defined in claim 1,
which process comprises reduction of a compound of formula (IA-4)




wherein all the symbols are as defined in claim 1 or 2.

15. A process for the preparation of a compound of formula (I) as defined in claim 1, which is of formula (I-2C)




wherein R¹⁵ is halogen atom and the other symbols are as defined in claim 1, which process comprises reduction of a compound of formula (IA-5)




wherein R^{15} is halogen atom, and the other symbols are as defined in claim 1 or 2.

16. A process for the preparation of a prodrug compound of formula (IA) as defined in claim 2, which is of formula (IA-1)




wherein R^{22} is hydrogen atom or hydroxy, and the other symbols are as defined in claim 1 or 2, which process comprises hydrolysis under acidic conditions of a compound of formula (III)




wherein R^{21} is hydrogen atom or hydroxy protecting group which may be eliminated under acidic conditions, and the other symbols are as defined in claim 1, 2 or 16.

17. A process for the preparation of a prodrug compound of formula (IA) as defined in claim 2, which is of formula (IA-2)



wherein R^{23} is C1-4 alkoxy and the other symbols are as defined in claim 1 or 2, which process comprises O-alkylation of a compound of formula (IA-3)



wherein all the symbols are as defined in claim 1 or 2.

18. A process for the preparation of a prodrug compound of formula (IB) as defined in claim 3, which process comprises amidation of a compound of formula (I-1) as defined in claim 12 with a compound of formula (IV)



wherein all the symbols are as defined in claim 3.

19. A process for the preparation of a prodrug compound of formula (IC) as defined in claim 4, which process comprises hydrolysis under acidic conditions of a compound of formula (V)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 98 30 0769

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 98 30 0769

DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim	CLASSIFICATION OF THE APPLICATION (INCL.4)
Category	Citation of document with indication, where appropriate, of relevant passages		
D, Y	US 4 132 738 A (KLUENDER HAROLD C ET AL) 2 January 1979 * claims *	1-22	C07C405/00 A61K31/557
X	US 4 363 817 A (BIDDLECOM WILLIAM G) 14 December 1982 * column 2, line 14 - line 51; claims *	4,9,12, 16-22	
Y	US 4 336 404 A (BIDDLECOM WILLIAM G ET AL) 22 June 1982 * claims *	1-22	
			TECHNICAL FIELDS SEARCHED (INCL.4)
			C07C
<p>The present search report has been drawn up for all claims</p> <p>Place of search: THE HAGUE Date of completion of the search: 4 May 1999 Examiner: Berte, M</p> <p>CATEGORY OF CITED DOCUMENTS</p> <p>X: particularly relevant if taken alone Y: relevant if taken in combination with another document of the same category A: technological background D: non-written disclosure P: prior art document</p> <p>T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document of the prior art L: document cited for other reasons A: member of the same patent family, corresponding document</p>			

The annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on the patent document. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

04-05-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4132738 A	02-01-1979	AU 515772 B	30-04-1981
		AU 4449379 A	30-08-1979
		CA 1191132 A	30-07-1985
		DE 2902699 A	30-08-1979
		FR 2430403 A	01-02-1980
		FR 2473509 A	17-07-1981
		GB 2014989 A,B	05-09-1979
		GB 2099814 A,B	15-12-1982
		JP 1194012 C	12-03-1984
		JP 5411531 A	07-09-1979
		JP 58026910 B	06-06-1983
		SE 441673 B	28-10-1985
		SE 7813385 A	24-08-1979
		SE 453990 B	21-03-1988
		SE 8303910 A	08-07-1983
		SE 453830 B	07-03-1988
		SE 8303911 A	08-07-1983
		SE 445109 B	02-06-1986
		SE 8303912 A	08-07-1983
		US 4833157 A	23-05-1989
		US 4331688 A	25-05-1982
		US 4415592 A	15-11-1983
		US 4742080 A	03-05-1988
		US 4275224 A	23-06-1981
US 4363817 A	14-12-1982	AU 535434 B	22-03-1984
		AU 8773182 A	03-03-1983
		EP 0073397 A	09-03-1983
		JP 58039660 A	08-03-1983
		JP 60033827 B	05-08-1985
US 4336404 A	22-06-1982	NONE	

For more details about this annex, see Official Journal of the European Patent Office, No. 12/82

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.